UNITED STATES
SECURITIES and EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q


þQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 20152016

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-12537

QUALITY SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

California
(State or other jurisdiction of incorporation or organization)

18111 Von Karman Avenue, Suite 700,800, Irvine, California
(Address of principal executive offices)
95-2888568
(IRS Employer Identification No.)

92612
(Zip Code)
 
(949) 255-2600
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yesþ    No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes þ    No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer þ
Accelerated filer o
Non-accelerated filer o (Do not check if a smaller reporting company)
Small reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes o    Noþ

The number of outstanding shares of the Registrant’s common stock as of January 26, 201623, 2017 was 60,886,17362,437,163 shares.


     





QUALITY SYSTEMS, INC.

TABLE OF CONTENTS
FORM 10-Q
FOR THE THREE MONTHS ENDED DECEMBER 31, 20152016

 
Item    
Page
   
 PART I. FINANCIAL INFORMATION 
Item 1.Financial Statements. 
 Unaudited Consolidated Balance Sheets as of December 31, 20152016 and March 31, 20152016
 Unaudited Consolidated Statements of Comprehensive Income for the three and nine months ended December 31, 20152016 and 20142015
 Unaudited Consolidated Statements of Cash Flows for the nine months ended December 31, 20152016 and 20142015
 Notes to Unaudited Consolidated Financial Statements
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Item 3.Quantitative and Qualitative Disclosures about Market Risk.
Item 4.Controls and Procedures.
 PART II. OTHER INFORMATION 
Item 1.Legal Proceedings.
Item 1A.Risk Factors.
Unregistered Sales of Equity Securities and Use of Proceeds.
Item 3.Defaults Upon Senior Securities.
Item 4.Mine Safety Disclosure.
Item 5.Other Information.
Item 6.Exhibits.
 Signatures




2




PART I. FINANCIAL INFORMATION

ITEM 1.    FINANCIAL STATEMENTS.


QUALITY SYSTEMS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)
(Unaudited)
December 31, 2015 March 31, 2015December 31, 2016 March 31, 2016
ASSETS      
Current assets:      
Cash and cash equivalents$92,648
 $118,993
$23,994
 $27,176
Restricted cash and cash equivalents4,452
 2,419
4,647
 5,320
Marketable securities12,165
 11,592

 9,297
Accounts receivable, net92,592
 107,669
75,516
 94,024
Inventories662
 622
Inventory252
 555
Income taxes receivable10,565
 3,147
14,481
 32,709
Deferred income taxes, net24,074
 24,080
Prepaid expenses and other current assets14,111
 11,535
15,944
 14,910
Total current assets251,269
 280,057
134,834
 183,991
Equipment and improvements, net23,171
 20,807
26,097
 25,790
Capitalized software costs, net44,573
 40,397
12,995
 13,250
Deferred income taxes, net9,780
 8,198
Intangibles, net22,287
 27,689
74,722
 91,675
Goodwill73,513
 73,571
185,888
 188,837
Other assets18,577
 18,000
18,703
 19,049
Total assets$433,390
 $460,521
$463,019
 $530,790
      
LIABILITIES AND SHAREHOLDERS’ EQUITY   
LIABILITIES AND SHAREHOLDERS' EQUITY   
Current liabilities:      
Accounts payable$10,250
 $10,018
$5,223
 $11,126
Deferred revenue55,146
 66,343
49,763
 57,935
Accrued compensation and related benefits16,345
 24,051
18,620
 18,670
Income taxes payable53
 10,048
8
 91
Dividends payable10,726
 10,700
Other current liabilities38,575
 33,924
44,338
 50,238
Total current liabilities131,095
 155,084
117,952
 138,060
Deferred revenue, net of current1,127
 1,349
1,312
 1,335
Deferred compensation6,667
 5,750
6,738
 6,357
Line of credit25,000
 105,000
Other noncurrent liabilities9,918
 14,798
14,267
 10,661
Total liabilities148,807
 176,981
165,269
 261,413
Commitments and contingencies (Note 12)

 

Shareholders’ equity:   
Common Stock   
$0.01 par value; authorized 100,000 shares; issued and outstanding 60,886 and 60,303 shares at December 31, 2015 and March 31, 2015, respectively609
 603
Commitments and contingencies (Note 13)

 

Shareholders' equity:   
Common stock   
$0.01 par value; authorized 100,000 shares; issued and outstanding 62,437 and 60,978 shares at December 31, 2016 and March 31, 2016, respectively624
 610
Additional paid-in capital210,184
 198,650
225,967
 211,262
Accumulated other comprehensive loss(517) (192)(653) (481)
Retained earnings74,307
 84,479
71,812
 57,986
Total shareholders’ equity284,583
 283,540
Total liabilities and shareholders’ equity$433,390
 $460,521
Total shareholders' equity297,750
 269,377
Total liabilities and shareholders' equity$463,019
 $530,790

The accompanying notes are an integral part of these consolidated financial statements.

3




QUALITY SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands, except per share data)
(Unaudited)
Three Months Ended December 31, Nine Months Ended December 31,Three Months Ended December 31, Nine Months Ended December 31,
2015 2014 2015 20142016 2015 2016 2015
Revenues:              
Software license and hardware$16,150
 $21,428
 $52,026
 $60,505
$16,995
 $16,150
 $48,966
 $52,026
Software related subscription services11,705
 11,864
 36,388
 31,266
22,546
 11,705
 63,911
 36,388
Total software, hardware and related27,855
 33,292
 88,414
 91,771
39,541
 27,855
 112,877
 88,414
Support and maintenance39,519
 43,045
 125,408
 125,985
39,924
 39,519
 116,905
 125,408
Revenue cycle management and related services21,594
 20,392
 62,630
 54,517
20,048
 21,594
 62,037
 62,630
Electronic data interchange and data services20,643
 19,051
 61,413
 56,276
21,790
 20,643
 65,527
 61,413
Professional services7,421
 7,644
 26,700
 33,288
6,565
 7,421
 19,893
 26,700
Total revenues117,032
 123,424
 364,565
 361,837
127,868
 117,032
 377,239
 364,565
Cost of revenue:              
Software license and hardware6,530
 7,295
 20,149
 22,326
5,680
 6,530
 19,227
 20,149
Software related subscription services5,533
 5,194
 17,454
 15,029
9,345
 5,533
 27,107
 17,454
Total software, hardware and related12,063
 12,489
 37,603
 37,355
15,025
 12,063
 46,334
 37,603
Support and maintenance7,537
 7,365
 23,874
 21,064
7,299
 7,537
 20,903
 23,874
Revenue cycle management and related services14,381
 14,246
 43,573
 40,154
13,462
 14,381
 42,052
 43,573
Electronic data interchange and data services12,437
 11,956
 37,302
 35,970
12,662
 12,437
 38,232
 37,302
Professional services7,367
 8,304
 24,008
 32,780
5,904
 7,367
 19,643
 24,008
Total cost of revenue53,785
 54,360
 166,360
 167,323
54,352
 53,785
 167,164
 166,360
Gross profit63,247
 69,064
 198,205
 194,514
73,516
 63,247
 210,075
 198,205
Operating expenses:              
Selling, general and administrative39,395
 41,482
 115,962
 116,893
37,542
 39,395
 120,913
 115,962
Research and development costs14,518
 18,468
 49,584
 51,602
Research and development costs, net19,714
 14,518
 56,230
 49,584
Amortization of acquired intangible assets897
 904
 2,692
 2,795
2,568
 897
 7,889
 2,692
Restructuring costs231
 
 4,685
 
Total operating expenses54,810
 60,854
 168,238
 171,290
60,055
 54,810
 189,717
 168,238
Income from operations8,437
 8,210
 29,967
 23,224
13,461
 8,437
 20,358
 29,967
Interest income (expense), net49
 (82) 392
 41
Interest income
 60
 9
 406
Interest expense(629) (11) (2,445) (14)
Other expense, net(43) 
 (147) (17)(4) (43) (146) (147)
Income before provision for income taxes8,443
 8,128
 30,212
 23,248
12,828
 8,443
 17,776
 30,212
Provision for income taxes1,141
 1,452
 8,233
 6,659
2,342
 1,141
 3,950
 8,233
Net income$7,302
 $6,676
 $21,979
 $16,589
$10,486
 $7,302
 $13,826
 $21,979
Other comprehensive income:              
Foreign currency translation (net of tax)(7) (101) (291) (177)
Unrealized gain (loss) on marketable securities (net of tax)(29) 68
 (34) 94
Foreign currency translation, net of tax(89) (7) (182) (291)
Unrealized gain (loss) on marketable securities, net of tax
 (29) 10
 (34)
Comprehensive income$7,266
 $6,643
 $21,654
 $16,506
$10,397
 $7,266
 $13,654
 $21,654
Net income per share:              
Basic$0.12
 $0.11
 $0.36
 $0.28
$0.17
 $0.12
 $0.22
 $0.36
Diluted$0.12
 $0.11
 $0.36
 $0.27
$0.17
 $0.12
 $0.22
 $0.36
Weighted-average shares outstanding:              
Basic60,867
 60,272
 60,548
 60,250
62,093
 60,867
 61,645
 60,548
Diluted61,279
 60,855
 61,190
 60,813
62,093
 61,279
 61,900
 61,190
Dividends declared per common share$0.175
 $0.175
 $0.525
 $0.525
$
 $0.175
 $
 $0.525
The accompanying notes are an integral part of these consolidated financial statements.

4




QUALITY SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Nine Months Ended December 31,Nine Months Ended December 31,
2015 20142016 2015
Cash flows from operating activities:      
Net income$21,979
 $16,589
$13,826
 $21,979
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation6,577
 6,755
7,562
 6,577
Amortization of capitalized software costs7,428
 10,190
6,626
 7,428
Amortization of other intangibles5,402
 5,371
16,953
 5,402
Amortization of debt issuance costs807
 
Loss on disposal of equipment and improvements158
 12
452
 158
Provision for bad debts2,107
 38
2,503
 2,107
Provision for inventory obsolescence118
 71
369
 118
Share-based compensation2,328
 2,627
5,177
 2,328
Deferred income taxes741
 (20)1,367
 741
Change in fair value of contingent consideration1,201
 1,533
3,797
 1,201
Loss on disposition of Hospital Solutions Division1,366
 

 1,366
Changes in assets and liabilities, net of amounts acquired:   
Changes in assets and liabilities:   
Accounts receivable11,313
 8,779
16,005
 11,313
Inventories(160) 98
Inventory(66) (160)
Accounts payable6
 (1,084)(5,983) 6
Deferred revenue(10,320) (3,897)(8,195) (10,320)
Accrued compensation and related benefits(7,706) 3,635
(50) (7,706)
Income taxes(18,395) 4,868
18,060
 (18,395)
Deferred compensation917
 668
381
 917
Other assets and liabilities2,232
 2,473
1,832
 2,232
Net cash provided by operating activities27,292
 58,706
81,423
 27,292
Cash flows from investing activities:      
Additions to capitalized software costs(11,604) (9,535)(6,371) (11,604)
Additions to equipment and improvements(9,926) (5,444)(8,242) (9,926)
Proceeds from sales and maturities of marketable securities5,310
 10,352
9,291
 5,310
Purchases of marketable securities(6,024) (10,995)
 (6,024)
HealthFusion working capital adjustment payment
(282) 
Net cash used in investing activities(22,244) (15,622)(5,604) (22,244)
Cash flows from financing activities:      
Principal repayments on line of credit(80,000) 
Proceeds from issuance of shares under employee plans732
 170
999
 732
Dividends paid(32,125) (32,073)
 (32,125)
Payment of contingent consideration related to acquisitions
 (686)
Net cash used in financing activities(31,393) (32,589)(79,001) (31,393)
Net increase (decrease) in cash and cash equivalents(26,345) 10,495
Net increase decrease in cash and cash equivalents(3,182) (26,345)
Cash and cash equivalents at beginning of period118,993
 103,145
27,176
 118,993
Cash and cash equivalents at end of period$92,648
 $113,640
$23,994
 $92,648

5




QUALITY SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS – (Continued)
(In thousands)
(Unaudited)
Nine Months Ended December 31,Nine Months Ended December 31,
2015 20142016 2015
Supplemental disclosures of cash flow information:      
Cash paid during the period for income taxes, net of refunds$25,574
 $1,523
Cash paid for income taxes$4,455
 $27,653
Cash refunds from income taxes$19,932
 $2,079
Cash paid for interest$1,670
 $
Common stock issued for Mirth share-based contingent consideration$9,273
 $
$9,273
 $9,273
Non-cash investing and financing activities:      
Tenant improvement allowance from landlord$3,094
 $1,324
Dividends declared but not paid$10,726
 $10,697
$
 $10,726
Unpaid additions to equipment and improvements$226
 $158
$80
 $226
The accompanying notes are an integral part of these consolidated financial statements.


6



QUALITY SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands, except shares and per share data)
(Unaudited)
1. Summary of Significant Accounting Policies
Principles of Consolidation. The consolidated financial statements include the accounts of Quality Systems, Inc. and its wholly-owned subsidiaries which consist of NextGen Healthcare Information Systems, LLC (“NextGen”), NextGen RCM Services, LLC, QSI Management, LLC, Quality Systems India Healthcare Private Limited (“QSIH”), ViaTrack Systems, LLC (“ViaTrack”), Matrix Management Solutions, LLC, and Mirth LLC and Mirth Limited (“Mirth”) (collectively, the “Company”). Each of the terms “we,” “us,” or “our” as used herein refers collectively to the Company, unless otherwise stated. All intercompany accounts and transactions have been eliminated.
On October 22, 2015, we closed an Asset Purchase Agreement with Quadramed Affinity Corporation (part of the Harris Operating Group of Constellation Software Inc.) in which we sold and assigned substantially all assets and liabilities of the Hospital Solutions Division (“Hospital disposition”). The results of operations and cash flows for the Hospital Solutions Division are reflected in the accompanying consolidated financial statements through the date of disposition. See Note 3 for additional details.
Basis of Presentation. The accompanying unaudited consolidated financial statements as of December 31, 20152016 and for the three and nine months ended December 31, 2015 and 20142016 have been prepared in accordance with the requirements of Quarterly Report on Form 10-Q and Article 10 of the Securities and Exchange Commission Regulation S-X and therefore do not include all information and notes which would be presented were such consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015.2016. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair statement of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year.
Beginning in the first quarter of fiscal 2016, we presented certain components of revenue within the consolidated statements of comprehensive income in a format intended to group like-kind products and services and disaggregate the other services category of revenue, which has continued to comprise a larger percentage of total revenue. More specifically, the primary changes to the presentation of revenue included:

Revenue from software-as-a-service (SaaS), hosting services, and other software related subscriptions are now aggregated into a new software related subscription services category of revenue. Previously, revenue from software related subscriptions services was reported within the other services category of revenue.

Revenue from annual software licenses that was also previously reported within the other services category of revenue is now reported within the software license and hardware category of revenue.

Revenue from all other services, including implementation, training, and consulting, are now aggregated into a single professional services category of revenue that excludes software related subscription services and annual software licenses, as noted above.

Each of the corresponding components of cost of revenue has also been revised in a manner that is consistent with the new presentation of revenue described above.
For informational and comparability purposes, we have recast our previously reported consolidated statements of comprehensive income to provide historical information on a basis consistent with the new reporting format of revenue and cost of revenue. The reclassification of revenue and cost of revenue within the consolidated statements of comprehensive income has no impact on previously reported net income or earnings per share and no impact on the previously reported consolidated balance sheets, statements of stockholders' equity, and statements of cash flow.
References to amounts in the consolidated financial statement sections are in thousands, except shares and per share data, unless otherwise specified.
Significant Accounting Policies. Effective July 1, 2016, we revised our reportable operating segments (see Note 14). There have been no other material changes to the significant accounting policies from those disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015.2016.

7



Share-Based Compensation. The following table shows total share-based compensation expense included in the consolidated statements of comprehensive income for the three and nine months ended December 31, 20152016 and 2014:2015:
 Three Months Ended December 31, Nine Months Ended December 31,
 2015 2014 2015 2014
Costs and expenses:       
Cost of revenue$101
 $105
 $300
 $283
Research and development costs67
 113
 280
 293
Selling, general and administrative575
 752
 1,748
 2,051
Total share-based compensation743
 970
 2,328
 2,627

The total income tax benefit related to share-based compensation was $225 and $313 for the three months ended December 31, 2015 and 2014, respectively. For the nine months ended December 31, 2015 and 2014, total income tax benefit related to share-based compensation was $701 and $825, respectively.
 Three Months Ended December 31, Nine Months Ended December 31,
 2016 2015 2016 2015
Costs and expenses:       
Cost of revenue$144
 $101
 $459
 $300
Research and development costs, net273
 67
 690
 280
Selling, general and administrative1,584
 575
 4,028
 1,748
Total share-based compensation2,001
 743
 5,177
 2,328
Income tax benefit(718) (225) (1,825) (701)
Decrease in net income$1,283
 $518
 $3,352
 $1,627

Recent Accounting Standards. Recent accounting pronouncements requiring implementation in future periods are discussed below or in the notes, where applicable.
In November 2015,2016, the FASB issued Accounting Standards Update No. 2015-17,("ASU") 2016-18, Balance Sheet ClassificationStatement of Deferred Taxes ("Cash Flows (Topic 230): Restricted Cash (“ASU 2015-17"2016-18”)., which simplifiesASU 2016-18 provides guidance on the presentationclassification of deferred income taxes by requiring deferred tax liabilitiesrestricted cash and assets to be classified as noncurrentcash equivalents in a classifiedthe statement of financial position. The new guidance is effective for financial statements issued for annual periods beginning after December 15, 2016,cash flows. Although it does not provide a definition of restricted cash or restricted cash equivalents, it states that amounts generally described as restricted cash and interim periods within those annual periods. Early adoption is permittedrestricted cash equivalents should be included with cash and may be applied either prospectively or retrospectively. This guidance is effective for us forcash equivalents when reconciling the quarter ending June 30, 2016. We are currently evaluatingbeginning-of-period and end-of period total amounts shown on the timingstatement of adoption and potential impact of implementation of this updated authoritative guidance on our consolidated financial statements.
In September 2015, the FASB issued Accounting Standards Update No. 2015-16, Simplifying the Accounting for Measurement-Period Adjustments ("cash flows. ASU 2015-16"), which eliminates the requirement to restate prior period financial statements for measurement period adjustments following a business combination. The new guidance requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. ASU 2015-162016-18 is effective for interim and annual reporting periods beginning after December 15, 2015 and early2017. Early adoption is permitted. This guidancepermitted, including adoption in an interim period. ASU 2016-18 is effective for us forin the first quarter ending March 31, 2016. Weof fiscal 2019, and we do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.
In July 2015,October 2016, the FASB issued Accounting Standards Update No. 2015-11,ASU 2016-16, Simplifying the MeasurementIncome Taxes: Intra-Entity Transfers of Assets Other Than Inventory ("ASU 2015-11"2016-16"), which replaces the concept of subsequently measuring inventory at 'lower of cost or market' with that of 'lower of cost and net realizable value'. The guidance only applies to inventories for which cost is determined by methods other than last-in first-out (LIFO) and the retail inventory method (RIM). ASU 2015-112016-16 requires the recognition of current and deferred income taxes for intra-entity asset transfers when the transaction occurs. ASU 2016-16 is effective for fiscal yearsinterim and annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years.2017. Early adoption is permitted. This guidanceASU 2016-16 is effective for us in the first quarter of fiscal 2019, and we are currently in the process of evaluating the potential impact of adoption of this updated authoritative guidance on our consolidated financial statements.


In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 is intended to add and clarify guidance on the classification of certain cash receipts and cash payments in the statement of cash flows to eliminate diversity in practice related to how such cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. ASU 2016-15 is effective for us in the first quarter of fiscal year ending March 31, 2018. We2019, and we do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.
In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). ASU 2016-09 simplifies the accounting for and reporting on share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for interim and annual reporting periods beginning after December 15, 2016, with early adoption permitted. The amendments in this update are to be applied differently upon adoption with certain amendments being applied prospectively, retrospectively and under a modified retrospective transition method. We expect to adopt ASU 2016-09 in the first quarter of fiscal 2018, and we do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”), which is intended to improve financial reporting about leasing transactions. The new guidance will require lessees to recognize on their balance sheets the assets and liabilities for the rights and obligations created by leases and to disclose key information about the leasing arrangements. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. ASU 2016-02 is effective for us in the first quarter of fiscal 2020. We are currently in the process of evaluating the potential impact of adoption of this updated authoritative guidance on our consolidated financial statements.
In April 2015, the FASB issued Accounting Standards Update No.ASU 2015-05, Customer’s Accounting for Fees Paid in a Cloud Arrangement ("ASU 2015-05"), which requires a customer to determine whether a cloud computing arrangement contains a software license that should be accounted for as internal-use software or as a service contract. ASU 2015-05 is effective for interim and annual reporting periods beginning after December 15, 2015, with early adoption permitted. Upon adoption, an entity has the option to apply the provisions of ASU 2015-05 either prospectively to all arrangements entered into or materially modified, or retrospectively. We do not expect theThe adoption of this new standard todid not have a material impact on our consolidated financial statements.
In August 2014, the FASB issued Accounting Standards Update No.ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern ("ASU 2014-15"), which incorporates and expands upon certain principles that currently exist in U.S. auditing standards. ASU 2014-15 provides guidance regarding management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. The new standard requires management to perform interim and annual evaluations and sets forth principles for considering the mitigating effect of management's plans. The standard mandates certain disclosures when conditions give rise to substantial doubt about a company’s ability to continue as a going concern within one year from the financial statement issuance date. ASU 2014-15 is effective for annual reporting periods ending after December 15, 2016, and all annual and interim periods thereafter. Early adoption is permitted. ASU 2014-15 is effective for us forcommencing fiscal year ending March 31, 2017. We do not expect theThe adoption of this new standard has not had, and is not expected to have, a materialan impact on our consolidated financial statements.statements.

8



In May 2014, the FASB, along with the International Accounting Standards Board, issued Accounting Standards Update No.ASU 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition.Recognition.  ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards and GAAP.  The core principle of this updated guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new standard also requires additional disclosure about revenue and provides improved guidance for multiple element arrangements. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, based on theIn July 2015 decision, and issuance of Accounting Standards Update No.the FASB issued ASU 2015-14, Deferral of Effective Date ("ASU 2015-14")by the FASB to delay the effective date by one year. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606) –Principal versus Agent Consideration ("ASU 2016-08"). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing ("ASU 2016-10”). In May 2016, the FASB issued ASU 2016-11, Revenue from Contracts with Customers (Topic 606) and Derivatives and Hedging (Topic 815) – Rescission of SEC Guidance Because of ASU 2014-09 and 2014-16 ("ASU 2016-11") and ASU 2016-12, Revenue from Contracts with Customers (Topic 606) –Narrow Scope Improvements and Practical Expedients ("ASU 2016-12"). The new ASUs do not change the core principle of the guidance in Topic 606 (as amended by ASU 2014-09), but rather help to provide further interpretive clarifications on the new guidance in ASU 2014-09. ASU 2014-09, as amended by ASU 2015-14, is effective for us in the first quarter of fiscal 2019. Companies are permitted to adopt this new guidance following either a full retrospective or modified retrospective approach. ASU 2014-09 is effective for us in
We have established a cross-functional team to assess the first quarterpotential impact of the new revenue standard. Our assessment process consists of reviewing our current accounting policies and practices to identify potential differences that would result from applying the requirements of the new standard to our revenue contracts and identifying appropriate changes to our business processes, systems and controls to support revenue recognition and disclosure requirements under the new standard. Our initial assessment of the impact of the new revenue standard on our current business processes, systems and controls are expected to be completed during fiscal 2019.  We2017. Additionally, we are currently evaluating the potential impact ofthat the implementation of this updated authoritative guidancenew revenue


standard will have on our consolidated financial statements.statements as well as selection of the method of adoption. We currently do not expect to implement this new standard prior to the required effective date.
We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

2. Fair Value Measurements

The following tables set forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis at December 31, 20152016 and March 31, 2015:2016:
Balance at Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3)Balance at Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3)
December 31,
2015
 December 31,
2016
 
ASSETS              
Cash and cash equivalents (1)$92,648
 $92,648
 $
 $
$23,994
 $23,994
 $
 $
Restricted cash and cash equivalents4,452
 4,452
 
 
4,647
 4,647
 
 
Marketable securities (2)12,165
 12,165
 
 
$109,265
 $109,265
 $
 $
$28,641
 $28,641
 $
 $
LIABILITIES              
Contingent consideration related to acquisitions$8,046
 $
 $
 $8,046
$18,367
 $
 $18,367
 $
$8,046
 $
 $
 $8,046
$18,367
 $
 $18,367
 $
Balance at Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3)Balance at Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3)
March 31,
2015
 March 31,
2016
 
ASSETS              
Cash and cash equivalents (1)$118,993
 $118,993
 $
 $
$27,176
 $27,176
 $
 $
Restricted cash and cash equivalents2,419
 2,419
 
 
5,320
 5,320
 
 
Marketable securities (2)11,592
 11,592
 
 
9,297
 9,297
 
 
$133,004
 $133,004
 $
 $
$41,793
 $41,793
 $
 $
LIABILITIES              
Contingent consideration related to acquisitions$16,155
 $
 $
 $16,155
$23,843
 $
 $
 $23,843
$16,155
 $
 $
 $16,155
$23,843
 $
 $
 $23,843

(1)Cash equivalents consist primarily of money market funds.
(2)Marketable securities consist of available-for-sale money market instruments and fixed-income securities, including certificates of deposit, corporate bonds and notes, and municipal securities.

OurThe contingent consideration liability is accounted for atas of December 31, 2016 relates to the acquisition of HealthFusion (see Note 3). Prior to December 31, 2016, we had assessed the fair value of the contingent consideration liability on a recurring basis and is adjustedany adjustments to fair value whensubsequent to the carrying value differs from fair value. The fair value adjustments aremeasurement period were reflected as a componentin the consolidated statements of selling, general and administrative expense.comprehensive income. Key assumptions includeincluded discount rates and probability-adjusted achievement estimates of strategiccertain revenue targets that arewere not observable in the market. The categorization of the framework used to measure fair value of the contingent consideration liability iswas previously considered to be within the Level 3 valuation hierarchy due to

9



the subjective nature of the unobservable inputs used. The fair valuesAs of the end of the measurement period on December 31, 2016, the actual revenue achievement rate was utilized to compute the ending contingent consideration liability. Accordingly, the contingent consideration liability were estimatedwas transferred into the Level 2 valuation hierarchy because the fair value was determined based on the probability of achieving certain business milestones.other significant observable inputs.


The following table presents activity in our financial assets and liabilities measured at fair value using significant unobservable inputs (Level 3), as of and for the nine months ended December 31, 2015:2016:
  Total Liabilities
Balance as of April 1, 2015 $16,155
Settlement of contingent consideration related to acquisitions (9,310)
Fair value adjustments 1,201
Balance as of December 31, 2015 $8,046
  Total Liabilities
Balance at April 1, 2016 $23,843
Settlement of contingent consideration related to Mirth (9,273)
Fair value adjustments 3,797
Transfer of HealthFusion contingent consideration to Level 2 (18,367)
Balance at December 31, 2016 $

During the nine months ended December 31, 2016, we issued shares of common stock to settle $9,273 in contingent consideration liabilities related to the acquisition of Mirth and recorded $3,797 of fair value adjustments to contingent consideration liabilities, of which $3,367 was related to HealthFusion and $430 was related to Mirth. During the three months ended December 31, 2016, we recorded a benefit of $2,033 for fair value adjustments of contingent consideration liabilities related to HealthFusion. The fair value adjustments to contingent consideration liabilities are included as a component of selling, general and administrative expense in the consolidated statements of comprehensive income.
We believe that the fair value of other financial assets and liabilities, including accounts receivable, accounts payable, and line of credit, approximate their respective carrying values due to their nominal credit risk.

Non-Recurring Fair Value Measurements
We have certain assets, including goodwill and other intangible assets, which are measured at fair value on a non-recurring basis and are adjusted to fair value only if an impairment charge is recognized. The categorization of the framework used to measure fair value of the assets is considered to be within the Level 3 valuation hierarchy due to the subjective nature of the unobservable inputs used. During the nine months ended December 31, 2015,2016, we recorded a $58 adjustment to Gennius goodwill based on additional information that became available during the measurement period about certain liabilities that had existed as of the acquisition date. There were no other adjustments to HealthFusion goodwill (see Note 3).

3. Business Combinations
HealthFusion Acquisition
On January 4, 2016, we completed our acquisition of HealthFusion Holdings, Inc. ("HealthFusion") pursuant to the Agreement and Plan of Merger (the “Merger Agreement"), dated October 30, 2015. HealthFusion provides Web-based, cloud computing software for physicians, medical billing service providers, and hospitals. Its flagship product, MediTouch®, is a fully-integrated, cloud-based software suite consisting of clearinghouse, practice management, electronic health records, and patient portals with rich functionality to enable mobility, workflow automation, and advanced reporting and analytics aimed primarily at small-to-mid-size physician practices. The acquisition of HealthFusion is part of our strategy to expand its client base and cloud-based solution capabilities in the ambulatory market. Over time, we plan to expand the HealthFusion platform to satisfy the needs of practices of increasing size and complexity.
The preliminary purchase price totals $183,049, which includes preliminary working capital and other customary adjustments and the fair value of such assets.contingent consideration related to an additional $25,000 of cash in the form of an earnout, subject to HealthFusion achieving certain revenue targets through December 31, 2016. The initial estimated fair value of contingent consideration of $16,700 was based on a Monte Carlo-based valuation model that considered, among other assumptions and inputs, our estimate of projected HealthFusion revenues. As of December 31, 2016, the fair value of the contingent consideration was $18,367.

3. Business Combinations and DisposalsThe acquisition was initially funded by a draw against the revolving credit agreement (see Note 7), a portion of which was subsequently repaid from existing cash on hand.
Gennius Acquisition
On March 11, 2015, we acquired Gennius, a provider of healthcare data analytics. The purchase price totaled $2,345. We accounted for the GenniusHealthFusion acquisition as a purchase business combination.combination using the acquisition method of accounting. The preliminary purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their preliminary estimated fair values as of the acquisition date. The preliminary fair values of acquired assets and liabilities assumed represent management’s estimate of fair value. value and are subject to change if additional information, such as changes to deferred taxes and/or working capital, becomes available. We expect to finalize the purchase price allocation as soon as practicable within the measurement period, but not later than one year following the acquisition date.
The preliminary estimated fair value of the acquired tangible and intangible assets and liabilities assumed were determined using multiple valuation approaches depending on the type of tangible or intangible asset acquired, including but not limited to the income approach, the excess earnings method and the relief from royalty method approach.
The preliminary amount of goodwill represents the excess of the preliminary purchase price over the preliminary net identifiable assets acquired and liabilities assumed. Goodwill primarily represents, among other factors, the value of synergies expected to be


realized and the assemblage of all assets that enable us to create new client relationships, neither of which qualify as separate amortizable intangible assets. Goodwill arising from the acquisition of GenniusHealthFusion was determined as the excess of the preliminary purchase price over the net acquisition date fair values of the acquired assets and the liabilities assumed, and is not deductible for tax purposes. The Gennius goodwill represents the expected future synergies resulting from the integration of the Gennius healthcare data analytics technology, which will enhance our current enterprise analytics competencies and broaden our business intelligence capabilities for addressing new value-based care requirements. GenniusHealthFusion operates under the NextGen Division.
our Software and Related Solutions segment. During the threenine months ended December 31, 2015,2016, we recorded a $58$2,949 adjustment to HealthFusion goodwill related to changes in deferred taxes based on additional information that became available during the measurement period about certain liabilities that had existed asfiling of the acquisition date.final tax returns.
The total preliminary purchase price for the GenniusHealthFusion acquisition is summarized as follows:
Initial purchase price$165,000
Contingent consideration16,700
Preliminary working capital and other adjustments1,349
Total preliminary purchase price$183,049
 Gennius
Total cash purchase price$2,345


10



The following table summarizes the purchase price allocation for the Gennius acquisition:
 Gennius
Fair value of the net tangible assets acquired and liabilities assumed: 
Other assets$4
Deferred revenues(37)
Other liabilities(131)
Total net tangible assets acquired and liabilities assumed(164)
Fair value of identifiable intangible assets acquired: 
Software technology1,800
Goodwill709
Total identifiable intangible assets acquired2,509
Total purchase price$2,345
The pro forma effects of the Gennius acquisition would not have been material to our results of operations and are therefore not presented.
 January 4, 2016
Preliminary fair value of the net tangible assets acquired and liabilities assumed: 
Acquired cash and cash equivalents$2,225
Accounts receivable, net1,514
Prepaid expenses and other current assets4,645
Equipment and improvements, net767
Capitalized software costs, net307
Other assets700
Accounts payable(1,085)
Accrued compensation and related benefits(533)
Deferred revenue(1,067)
Deferred income taxes, net(9,078)
Other liabilities(2,721)
Total preliminary net tangible assets acquired and liabilities assumed(4,326)
Preliminary fair value of identifiable intangible assets acquired: 
Software technology42,500
Customer relationships28,500
Trade name4,000
Goodwill112,375
Total preliminary identifiable intangible assets acquired187,375
Total preliminary purchase price$183,049

Hospital Disposition
On October 22, 2015, we closed an Asset Purchase Agreement (the “Purchase Agreement”) with Quadramed Affinity Corporation in which we sold and assigned substantially all assets and liabilities of the Hospital Solutions Division. We believe that the Hospital disposition will allow us to focus our efforts and resources on our core ambulatory business. The financial terms of the transaction and the amount of consideration received were not significant. Since the Hospital disposition did not and is not expected to have a major effect on our operations and financial results, separate discontinued operations reporting is not provided.
We incurred a preliminary loss on the Hospital disposition of $1,366 in the three months ended December 31, 2015, which was recorded in our consolidated statements of comprehensive income as a component of selling, general and administrative expense. The loss was measured as the total consideration received and expected to be received less the lower of carrying value or fair value of the Hospital Solutions Division. Additionally, we incurred $387 in direct incremental costs of disposition and $335 in severance and other employee-related costs in connection with the Hospital disposition during the three months ended December 31, 2015.
Pursuant to the Purchase Agreement, the initial purchase price is subject to certain purchase price adjustments for changes in Net Tangible Assets (as defined in the Purchase Agreement) and future collections of the assigned accounts receivable through July 2016.
4. Goodwill
We test goodwill for impairment annually during our first fiscal quarter, referred to as the annual test date. We will also test for impairment between annual test dates if an event occurs or circumstances change that would indicate the carrying amount may be impaired. During the three months ended December 31, 2015, weWe have not identified any events or circumstances as of December 31, 2016 that would require an interim goodwill impairment test. During the nine months ended December 31, 2016, we recorded certain adjustment to HealthFusion goodwill (see Note 3).
We do not amortize goodwill as it has been determined to have an indefinite useful life.
We have also determined that the change in reportable operating segments as a result of our ongoing reorganization efforts (see Note 14) did not have a significant impact on the amount of goodwill that is allocated to each reporting unit and each reportable operating segment.Goodwill by reporting unitreportable operating segment consists of the following:
 March 31,
2015
 December 31,
2015
NextGen Division$33,992
 $33,934
RCM Services Division32,290
 32,290
QSI Dental Division (1)7,289
 7,289
Total goodwill$73,571
 $73,513

(1) QSI Dental Division goodwill is presented on a basis consistent with that of our management reporting structures. However, for the purposes of assessing goodwill for impairment annually and as otherwise may be required, the QSI Dental Division goodwill is allocated to the reporting units that derive cash flows from the products associated with the acquired goodwill. For all periods presented in this report, the allocation resulted in substantially all of the QSI Dental Division goodwill being ascribed to the NextGen Division.
 December 31,
2016
 March 31,
2016
Software and Related Solutions$153,598
 $156,547
RCM and Related Services32,290
 32,290
Total goodwill$185,888
 $188,837


11




5. Intangible Assets

Our definite-lived intangible assets, other than capitalized software development costs, are summarized as follows:
December 31, 2015December 31, 2016
Customer Relationships Trade Name and Contracts Software Technology TotalCustomer Relationships Trade Name and Contracts Software Technology Total
Gross carrying amount$22,050
 $3,368
 $25,310
 $50,728
$50,550
 $5,480
 $67,810
 $123,840
Accumulated amortization(17,270) (2,567) (8,604) (28,441)(26,693) (1,821) (20,604) (49,118)
Net intangible assets$4,780
 $801
 $16,706
 $22,287
$23,857
 $3,659
 $47,206
 $74,722
March 31, 2015March 31, 2016
Customer Relationships Trade Name and Contracts Software Technology TotalCustomer Relationships Trade Name and Contracts Software Technology Total
Gross carrying amount$22,050
 $3,368
 $25,310
 $50,728
$50,550
 $7,368
 $67,810
 $125,728
Accumulated amortization(14,986) (2,159) (5,894) (23,039)(19,618) (2,895) (11,540) (34,053)
Net intangible assets$7,064
 $1,209
 $19,416
 $27,689
$30,932
 $4,473
 $56,270
 $91,675
Amortization expense related to customer relationships and trade name and contracts that is includedrecorded as operating expenses in the consolidated statements of comprehensive income was $898$2,568 and $905$898 for the three months ended December 31, 20152016 and 2014,2015, respectively. Amortization expense related to software technology that is included inrecorded as cost of revenue for software licensewas $3,007 and hardware was $903 and $858 for the three months ended December 31, 20152016 and 2014,2015, respectively.
Amortization expense related to customer relationships and trade name and contracts that is includedrecorded as operating expenses in the consolidated statements of comprehensive income was $2,692$7,889 and $2,811$2,692 for the nine months ended December 31, 20152016 and 2014,2015, respectively. Amortization expense related to software technology that is included inrecorded as cost of revenue for software licensewas $9,064 and hardware was $2,710 and $2,560 for the nine months ended December 31, 20152016 and 2014,2015, respectively.
The following table representssummarizes the remaining estimated amortization of definite-lived intangible assets as of December 31, 2015:2016:
Amortization Expense Recorded As:
Operating Expense Cost of Revenue Total
For the year ended March 31,      
2016 (remaining three months)$1,801
20176,733
2017 (remaining three months)2,527
 2,963
 5,490
20184,481
7,264
 11,851
 19,115
20193,697
4,852
 11,851
 16,703
20203,352
3,855
 11,851
 15,706
2021 and beyond2,223
20213,006
 7,968
 10,974
2022 and beyond6,012
 722
 6,734
Total$22,287
$27,516
 $47,206
 $74,722

6.Capitalized Software Costs

Our capitalized software costs are summarized as follows:
December 31,
2015
 March 31,
2015
December 31,
2016
 March 31,
2016
Gross carrying amount$125,559
 $113,955
$103,070
 $96,699
Accumulated amortization(80,986) (73,558)(90,075) (83,449)
Net capitalized software costs$44,573
 $40,397
$12,995
 $13,250
Amortization expense related to capitalized software costs was $2,499$1,807 and $3,073$2,499 for the three months ended December 31, 2016 and 2015, respectively, and 2014, respectively.is recorded as cost of revenue in the consolidated statements of comprehensive income. Amortization
Amortization

expense related to capitalized software costs was $7,428$6,626 and $10,190$7,428 for the nine months ended December 31, 2016 and 2015, and 2014, respectively.

12



The following table presents the remaining estimated amortization of capitalized software costs as of December 31, 2015.2016. The estimated amortization is comprised of (i) amortization of released products and (ii) the expected amortization for products that are not yet available for sale based on their estimated economic lives and projected general release dates.
For the year ended March 31,  
2016 (remaining three months)$2,500
20176,800
2017 (remaining three months)$1,500
20181,800
5,300
20195,900
4,300
20206,700
1,895
2021 and beyond20,873
Total$44,573
$12,995

7. Line of Credit
On January 4, 2016, we entered into a $250,000 revolving credit agreement (“Credit Agreement”) with JP Morgan Chase Bank, N.A., as administrative agent, U.S. Bank National Association, as syndication agent, and certain other lenders. The Credit Agreement is secured by substantially all of our existing and future property and material domestic subsidiaries. The Credit Agreement provides a subfacility of up to $10,000 for letters of credit and a subfacility of up to $10,000 for swing-line loans. The Credit Agreement matures on January 4, 2021 and the full balance of the revolving loans and all other obligations under the agreement must be paid at that time. The revolving loans under the Credit Agreement will be available for letters of credit, working capital and general corporate purposes. We were in compliance with all covenants under the Credit Agreement as of December 31, 2016.
As of December 31, 2016, we had $25,000 in outstanding loans and $225,000 of unused credit under the Credit Agreement.
During the three months ended December 31, 2016, we recorded $359 of interest expense and $269 in amortization of deferred debt issuance costs related to the Credit Agreement. During the nine months ended December 31, 2016, we recorded $1,631 of interest expense and $807 in amortization of deferred debt issuance costs related to the Credit Agreement.

8. Composition of Certain Financial Statement Captions

Accounts receivable may include amounts invoiced but not yet renderedfor undelivered products and services at each period end. Undelivered products and services are included as a component of the deferred revenue balance on the accompanying consolidated balance sheets.
December 31,
2015
 March 31,
2015
December 31,
2016
 March 31,
2016
Accounts receivable, gross$103,009
 $119,807
$86,388
 $104,467
Sales return reserve(7,128) (8,835)(8,623) (7,541)
Allowance for doubtful accounts(3,289) (3,303)(2,249) (2,902)
Accounts receivable, net$92,592
 $107,669
$75,516
 $94,024

Inventories are summarized as follows:
 December 31,
2015
 March 31,
2015
Computer systems and components$662
 $622
Inventory is comprised of computer systems and components.

Prepaid expenses and other current assets are summarized as follows:
December 31,
2015
 March 31,
2015
December 31,
2016
 March 31,
2016
Prepaid expenses$10,469
 $9,941
$13,448
 $11,804
Other current assets3,642
 1,594
2,496
 3,106
Prepaid expenses and other current assets$14,111
 $11,535
$15,944
 $14,910



Equipment and improvements are summarized as follows:
December 31,
2015
 March 31,
2015
December 31,
2016
 March 31,
2016
Computer equipment$40,773
 $42,668
$21,483
 $32,213
Internal-use software10,899
 10,201
Furniture and fixtures9,505
 10,408
10,561
 9,799
Leasehold improvements10,783
 9,767
16,538
 13,408
61,061
 62,843
Equipment and improvements, gross59,481
 65,621
Accumulated depreciation and amortization(37,890) (42,036)(33,384) (39,831)
Equipment and improvements, net$23,171
 $20,807
$26,097
 $25,790


13



Current and non-currentThe current portion of deferred revenuerevenues are summarized as follows:
December 31,
2015
 March 31,
2015
December 31,
2016
 March 31,
2016
Professional services$24,910
 $30,340
$22,005
 $23,128
Software license, hardware and other14,669
 17,638
10,469
 14,913
Support and maintenance10,239
 15,077
8,948
 11,902
Software related subscription services5,328
 3,288
8,341
 7,992
Deferred revenue$55,146
 $66,343
$49,763
 $57,935
Deferred revenue, net of current$1,127
 $1,349

Accrued compensation and related benefits are summarized as follows:
December 31,
2015
 March 31,
2015
December 31,
2016
 March 31,
2016
Payroll, bonus and commission$8,044
 $13,505
$10,617
 $9,683
Vacation8,301
 10,546
8,003
 8,987
Accrued compensation and related benefits$16,345
 $24,051
$18,620
 $18,670

Other current and non-currentnoncurrent liabilities are summarized as follows:
December 31,
2015
 March 31,
2015
December 31,
2016
 March 31,
2016
Contingent consideration and other liabilities related to acquisitions$8,313
 $9,124
$18,367
 $24,153
Care services liabilities4,647
 5,339
Customer credit balances and deposits4,700
 4,760
3,973
 4,123
Care services liabilities4,467
 2,381
Accrued EDI expense2,270
 2,604
Accrued consulting and outside services2,194
 3,650
Accrued self insurance expense1,898
 1,862
Accrued outsourcing costs1,613
 1,604
Deferred rent1,409
 828
Accrued legal expense3,266
 3,527
758
 864
Accrued acquisition costs3,252
 
Accrued royalties2,650
 2,063
740
 2,341
Accrued EDI expense2,327
 2,322
Accrued consulting2,225
 2,603
Self insurance reserve2,165
 2,290
Employee benefit plan withholdings639
 213
Sales tax payable333
 655
Other accrued expenses5,210
 4,854
5,497
 2,002
Other current liabilities$38,575
 $33,924
$44,338
 $50,238
      
Contingent consideration and other liabilities related to acquisitions$
 $7,581
Deferred rent6,012
 3,122
$9,538
 $6,577
Uncertain tax position and related liabilities3,906
 4,095
4,729
 4,084
Other non-current liabilities$9,918
 $14,798
Other noncurrent liabilities$14,267
 $10,661

8.


9. Income Taxes
The provision for income taxes for the three months ended December 31, 20152016 was $2,342 and 2014 was approximately $1,141 and $1,452, respectively. The effective tax rates were 13.5% and 17.9%the provision for income taxes for the three months ended December 31, 2015 was $1,141. The effective tax rates were 18.3% and 2014, respectively,13.5% for the three months ended December 31, 2016 and both periods reflect approximately three quarters of a full fiscal year impact of the research and development tax credit due to the timing of the expiration and retroactive reinstatement of the credit.2015, respectively. The effective rate for the three months ended December 31, 2015 decreased as2016 increased compared to the prior year period primarily due to a favorablethe impact of thelower qualifying production activity deductiondeductions in the three months ended December 31, 2015.current period, certain non-deductible acquisition-related costs, and a discrete valuation allowance, offset by federal and state research and development credit and other discrete adjustments.
The provision for income taxes for the nine months ended December 31, 20152016 was $3,950 and 2014 was approximately $8,233 and $6,659, respectively. The effective tax rates were 27.3% and 28.6%the provision for income taxes for the nine months ended December 31, 2015 was $8,233. The effective tax rates were 22.2% and 2014,27.3% for the nine months ended December 31, 2016 and 2015, respectively. The effective rate for the nine months ended December 31, 20152016 decreased as compared to the prior year period primarily due to a favorable impact of thediscrete adjustments for federal and state research and development credit, offset by non-deductible acquisition-related costs, lower qualifying production activity deductiondeductions in the nine months ended December 31, 2015.current period, and other discrete adjustments.

14



The deferred tax assets and liabilities have been shown net in the accompanying consolidated balance sheets based on the long-term or short-term nature of the items that give rise to the deferred amount.as noncurrent. We expect to receive the full benefit of the deferred tax assets recorded with the exception of a specificcertain state credits, state net operating loss carryforwards, and foreign accumulated minimum tax creditcredits, for which we have recorded a valuation allowance.
Uncertain tax positions
AsWe had liabilities of December 31, 2015, we had recorded a liability of $3,836$4,729 and $4,084 for unrecognized tax benefits related to various federal, state and local income tax matters.matters as of December 31, 2016 and March 31, 2016, respectively. If recognized, this amount would reduce our effective tax rate. The tax liability for the nine months ended December 31, 2015 increased from the prior year period by $3,059 due to changes in reserves for state and local income tax benefit related to prior year tax positions.
We are no longer subject to U.S. federal income tax examinations for tax years before 2012.2013. With few exceptions, we are no longer subject to state income tax examinations for tax years before 2011.2012. We do not anticipate that total unrecognized tax benefits will significantly change due to the settlement of audits or the expiration of statute of limitations within the next twelve months.

9.10. Earnings per Share

The dual presentation of “basic” and “diluted” earnings per share (“EPS”) is provided below. Shares discussedShare amounts below are in thousands.
Three Months Ended December 31, Nine Months Ended December 31,Three Months Ended December 31, Nine Months Ended December 31,
2015 2014 2015 20142016 2015 2016 2015
Earnings per share — Basic:       
Net income$7,302
 $6,676
 $21,979
 $16,589
$10,486
 $7,302
 $13,826
 $21,979
Basic net income per share:       
Weighted-average shares outstanding — Basic60,867
 60,272
 60,548
 60,250
62,093
 60,867
 61,645
 60,548
Basic net income per common share$0.12
 $0.11
 $0.36
 $0.28
Net income per common share — Basic$0.17
 $0.12
 $0.22
 $0.36
              
Earnings per share — Diluted:       
Net income$7,302
 $6,676
 $21,979
 $16,589
$10,486
 $7,302
 $13,826
 $21,979
Diluted net income per share:       
Weighted-average shares outstanding — Basic60,867
 60,272
 60,548
 60,250
Weighted-average shares outstanding62,093
 60,867
 61,645
 60,548
Effect of potentially dilutive securities412
 583
 642
 563

 412
 255
 642
Weighted-average shares outstanding — Diluted61,279
 60,855
 61,190
 60,813
62,093
 61,279
 61,900
 61,190
Diluted net income per common share$0.12
 $0.11
 $0.36
 $0.27
Net income per common share — Diluted$0.17
 $0.12
 $0.22
 $0.36

The computation of diluted net income per share does not include 3,054 and 3,015 options to acquire shares of common stock for the three and nine months ended December 31, 2016, respectively, because their inclusion would have an anti-dilutive effect on net income per share.

The computation of diluted net income per share does not include 1,839 and 1,789 options to acquire shares of common stock for the three and nine months ended December 31, 2015, respectively, because their inclusion would have an anti-dilutive effect on net income per share.
The computation of diluted net income per share does not include 1,731 and 1,653 options to acquire shares of common stock for the three and nine months ended December 31, 2014, respectively, because their inclusion would have an anti-dilutive effect on net income per share.



10.11. Share-Based Awards
Employee Stock Option and Incentive Plans
In October 2005, our shareholders approved a stock option and incentive plan (the “2005 Plan”) under which 4,800,000 shares of common stock were reserved for the issuance of awards, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock units, performance shares, performance units (including performance options) and other share-based awards. The 2005 Plan provides that our employees and directors may, at the discretion of the Board of Directors ("Board") or a duly designated compensation committee, be granted certain share-based awards. In the case of option awards granted under the 2005 Plan, the exercise price of each option is determined based on the date of grant and expire no later than 10 years from the date of grant. Awards granted pursuant to the 2005 Plan are subject to the vesting schedule or performance metrics set forth in the agreements pursuant to which they are granted. Upon a change of control of our Company, as such term is defined in the 2005 Plan, awards under the 2005 Plan will fully vest under certain circumstances. The 2005 Plan expired on May 25, 2015. As of December 31, 2015,2016, there were 1,702,326969,565 outstanding options and 26,279567 outstanding shares of restricted stock restricted stock units and performance based restricted stockawards under the 2005 Plan.

15



In August 2015, our shareholders approved a stock option and incentive plan (the “2015 Plan”Plan��) under which 11,500,000 shares of common stock were reserved for the issuance of awards, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock awards and restricted stock unit awards, performance stock awards and other share-based awards. The 2015 Plan provides that our employees and directors may, at the discretion of the Board of Directors or a duly designated compensation committee, be granted certain share-based awards. In the case of option awards granted under the 2015 Plan, the exercise price of each option is determined based on the date of grant and expire no later than 10 years from the date of grant. Awards granted pursuant to the 2015 Plan are subject to the vesting schedule or performance metrics set forth in the agreements pursuant to which they are granted. Upon a change of control of our Company, as such term is defined in the 2015 Plan, awards under the 2015 Plan will fully vest under certain circumstances. As of December 31, 2015,2016, there were 150,0001,994,750 outstanding options, 92,934933,165 outstanding shares of restricted stock awards, 123,082 outstanding shares of performance stock awards, and 11,551,2158,079,983 shares available for future grant under the 2015 Plan.
A summary ofThe following table summarizes the stock option transactions during the nine months ended December 31, 2015 follows:2016:
  
Number of
Shares
 
Weighted-
Average
Exercise
Price
per Share
 
Weighted-
Average
Remaining
Contractual
Life (years)
 
Aggregate
Intrinsic
Value
(in thousands)
Outstanding, April 1, 2015 1,636,176
 $24.82
 5.5 
Granted 564,000
 15.44
 7.5 

Exercised (300) 15.99
 6.4 $
Forfeited/Canceled (497,550) 24.75
 4.8 

Outstanding, December 31, 2015 1,702,326
 $21.79
 5.6 $552
Vested and expected to vest, December 31, 2015 1,570,577
 $22.11
 5.6 $485
Exercisable, December 31, 2015 633,116
 $28.16
 4.2 $10
  
Number of
Shares
 
Weighted-
Average
Exercise
Price
per Share
 
Weighted-
Average
Remaining
Contractual
Life (years)
 
Aggregate
Intrinsic
Value
(in thousands)
Outstanding, April 1, 2016 2,447,286
 $19.55
 6.3 $574
Granted 1,056,500
 12.82
 7.4  
Forfeited/Canceled (539,471) 22.13
 4.7 

Outstanding, December 31, 2016 2,964,315
 $16.68
 6.4 $377
Vested and expected to vest, September 30, 2016 2,652,038
 $16.93
 6.3 $329
Exercisable, December 31, 2016 586,120
 $25.05
 3.9 $11

We utilize the Black-Scholes valuation model for estimating the fair value of share-based compensation with the following assumptions:
 Nine Months Ended December 31,Three Months Ended December 31, Nine Months Ended December 31,
 2015 20142016 2015 2016 2015
Expected term  3.8 - 3.9 years  4.8 years6.3 years 3.9 years 6.0 - 6.6 years 3.8 - 3.9 years
Expected volatility 38.3% - 38.9% 36.4% - 36.6%37.1% 38.9% 36.9% - 37.4% 38.3% - 38.9%
Expected dividends 4.1% - 5.3% 4.3% - 4.4%—% 5.3% —% 4.1% - 5.3%
Risk-free rate 1.3% - 1.6% 1.7%1.5% 1.3% 1.2% - 1.5% 1.3% - 1.6%
The weighted-average grant date fair value of stock options granted during the nine months ended December 31, 2016 and 2015 was $4.92 and 2014 was $3.33 and $3.50 per share, respectively.

16




During the nine months ended December 31, 2015,2016, a total of 564,0001,056,500 options to purchase shares of common stock were granted under the 2005 and 2015 PlansPlan at an exercise price equal to the market price of our common stock on the date of grant. A summary of stock options granted under the 2005 and 2015 Plans during fiscal years 2016 and 2015 isgrant, as follows:summarized below:
Option Grant Date Number of Shares Exercise Price Vesting Terms (1) Expires
August 17, 2015 150,000
 $12.80
 Five years August 17, 2023
May 22, 2015 414,000
 $16.64
 Five years May 22, 2023
Fiscal year 2016 option grants 564,000
      
         
March 11, 2015 10,000
 $15.84
 Five years March 11, 2023
September 2, 2014 20,000
 $15.63
 Five years September 2, 2022
June 3, 2014 439,650
 $15.99
 Five years June 3, 2022
Fiscal year 2015 option grants469,650
      
Option Grant Date Number of Shares Exercise Price 
Vesting Terms (1)
 Expiration
November 1, 2016 50,000
 $12.71
 Four years November 1, 2024
July 11, 2016 150,000
 $12.60
 Four years July 11, 2024
May 31, 2016 100,000
 $12.71
 Five years May 31, 2024
May 25, 2016 216,500
 $12.78
 Four years May 25, 2024
May 24, 2016 540,000
 $12.93
 Four years May 24, 2024
Fiscal year 2017 grants 1,056,500
      

(1)Options vest in equal annual installments on each grant anniversary date commencing one year following the date of grant.
Non-vested stock option award activity during the nine months ended December 31, 2016 is summarized as follows:
  
Non-Vested
Number of
Shares
 
Weighted-
Average
Grant-Date
Fair Value
per Share
Outstanding, April 1, 2016 1,859,750
 $4.67
Granted 1,056,500
 4.92
Vested (276,595) 4.30
Forfeited/Canceled (261,460) 4.38
Outstanding, December 31, 2016 2,378,195
 $4.72
As of December 31, 2016, $8,662 of total unrecognized compensation costs related to stock options is expected to be recognized over a weighted-average period of 3.2 years. This amount does not include the cost of new options that may be granted in future periods or any changes in our forfeiture percentage. The total fair value of options vested during the nine months ended December 31, 2016 and 2015 was $1,189 and $1,564, respectively.
Restricted stock awards activity during the nine months ended December 31, 2016 is summarized as follows:
  
Number of
Shares
 
Weighted-
Average
Grant-Date
Fair Value
per Share
Outstanding, April 1, 2016 191,247
 $14.44
Granted 857,456
 12.81
Vested (68,309) 14.29
Canceled (46,662) 12.78
Outstanding, December 31, 2016 933,732
 $12.80
Share-based compensation expense related to restricted stock awards was $1,054 and $249 for the three months ended December 31, 2016 and 2015, respectively. Share-based compensation expense related to restricted stock awards was $2,571 and $664 for the nine months ended December 31, 2016 and 2015, respectively.
The weighted-average grant withdate fair value for the exceptionrestricted stock awards was estimated using the market price of the August 17, 2015common stock on the date of grant. The fair value of the restricted stock awards is amortized on a straight-line basis over the vesting period, which is generally two years.
As of December 31, 2016, $9,930 of total unrecognized compensation costs related to restricted stock awards is expected to be recognized over a weighted-average period of 2.2 years. This amount does not include the cost of new restricted stock awards that may be granted in future periods.
On December 29, 2016, the Compensation Committee of the Board granted 123,082 performance stock awards to certain executive officers. The performance stock awards vest in four equal increments on each of the first four anniversaries of the grant which vestsdate, subject in five equal annual installments beginning on July 1,each case to the executive officer’s continued service and achievement of certain Company performance goals, including strong Company stock price performance. Share-based compensation expense related to the performance stock awards was not significant for the three and nine months ended December 31, 2016.


Employee Share Purchase Plan
On August 11, 2014, our shareholders approved an Employee Share Purchase Plan (the “Purchase Plan”) under which 4,000,000 shares of common stock were reserved for future grant.  The Purchase Plan allows eligible employees to purchase shares through payroll deductions of up to 15% of total base salary at a price equal to 90% of the lower of the fair market values of the shares as of the beginning or the end of the corresponding offering period.  Any shares purchased under the Purchase Plan are subject to a six-month holding period.  Employees are limited to purchasing no more than 1,500 shares on any single purchase date and no more than $25,000 in total fair market value of shares during any one calendar year. As of December 31, 2015,2016, we have issued 95,190209,876 shares under the Purchase Plan and 3,904,8103,790,124 shares are available for future issuance.
Share-based compensation expense recorded for the employee share purchase plan was $70 and $70 for the three months ended December 31, 2016 and 2015, and $50 for the three months ended December 31, 2014
respectively. Share-based compensation expense recorded for the employee share purchase plan was $277 and $216 for the nine months ended December 31, 2015 and $59 for the nine months ended December 31, 2014.
Performance-Based Awards
On May 14, 2015, the Compensation Committee approved our fiscal year 2016 Executive Compensation Program (the "Program") for our named executive officers for fiscal year 2016, on May 20, 2015, our Compensation Committee approved the Program for our Interim Chief Financial Officer, and on June 3, 2015, our Compensation Committee approved the Program for our Chief Executive Officer (effective July 1, 2015). Under the incentive portion of the Program, the executive officers are eligible to receive cash bonuses based on meeting certain target increases in revenue and non-GAAP earnings per share for fiscal year 2016 and certain equity incentive awards, including a potential award of up to an aggregate of 320,000 restricted performance shares of our common stock vesting over a three year period based on the achievement of target average daily share prices for the thirty calendar day period ending April 30th of each of the subsequent three fiscal years. In addition, under the Program, a target pool of up to 400,000 options is available for new hires, promotions, and for certain high-performing, non-executive employees based on achievement in performance targets.
Share-based compensation expense associated with the restricted performance shares with market conditions under the Program is based on the grant date fair value measured at the underlying closing share price on the date of grant using a Monte Carlo-based valuation model.

17



Share-based compensation expense associated with the target pool of options under our equity incentive programs are initially based on the number of options expected to vest after assessing the probability that the performance criteria will be met. Cumulative adjustments are recorded quarterly to reflect subsequent changes in the estimated outcome of performance-related conditions. We utilize the Black-Scholes option valuation model with the assumptions in the table below to calculate the share-based compensation expense related to the options.
 Three Months Ended December 31, Nine Months Ended December 31,
 2015 2014 2015 2014
Expected term3.8 years 4.8 years  3.8 - 3.9 years  4.8 years
Expected volatility39.2% 36.2% 37.7% - 39.2% 36.2% - 36.5%
Expected dividends—% 4.4% 0.0% - 5.5% 4.3% - 5.0%
Risk-free rate1.5% 1.7% 1.1% - 1.6% 1.6% - 1.8%
Share-based compensation expense recorded for our performance-based awards was $143 for the three months ended December 31, 2015, and $133 for the three months ended December 31, 2014
Share-based compensation expense recorded for our performance-based awards was $290 for the nine months ended December 31, 2015 and $345 for the nine months ended December 31, 2014.
Non-vested stock option award activity, including employee stock options and performance-based awards, during the nine months ended December 31, 2015 is summarized as follows:
  
Non-Vested
Number of
Shares
 
Weighted-
Average
Grant-Date
Fair Value
per Share
Outstanding, April 1, 2015 1,068,290
 $5.81
Granted 564,000
 3.33
Vested (274,400) 5.70
Forfeited/Canceled (288,680) 5.34
Outstanding, December 31, 2015 1,069,210
 $4.39
As of December 31, 2015, $3,459 of total unrecognized compensation costs related to stock options is expected to be recognized over a weighted-average period of 3.4 years. This amount does not include the cost of new options that may be granted in future periods or any changes in our forfeiture percentage. The total fair value of options vested during the nine months ended December 31, 2015 and 2014 was $1,564 and $1,633, respectively.
Director Awards
On May 20, 2015, the Board of Directors approved our 2016 Director Compensation Program, pursuant to which each non-employee director is to be granted shares of restricted stock upon election or re-election to the Board of Directors. The shares of restricted stock will be granted promptly following shareholder approval and registration of our 2015 Equity Incentive Plan. The shares of restricted stock will be issued according to a standard form of restricted stock award agreement and pursuant to our 2015 Equity Incentive Plan, will carry a restriction requiring that the restricted stock vest in two equal installments over two consecutive years with the vesting dates being the next two meeting dates of our annual shareholders’ meeting following election or re-election to the Board of Directors.
Share-based compensation expense related to restricted stock was $249 for the three months ended December 31, 2015 and $245 for the three months ended December 31, 2014
Share-based compensation expense related to restricted stock was $664 for the nine months ended December 31, 2015 and $637 for the nine months ended December 31, 2014.

18



Restricted stock activity for the nine months ended December 31, 2015 is summarized as follows:
  
Number of
Shares
 
Weighted-
Average
Grant-Date
Fair Value
per Share
Outstanding, April 1, 2015 78,205
 $17.94
Granted 92,934
 12.86
Vested (50,426) 19.98
Canceled (1,500) 17.95
Outstanding, December 31, 2015 119,213
 $13.88
The weighted-average grant date fair value for the restricted stock was estimated using the market price of the common stock on the date of grant. The fair value of the restricted stock is amortized on a straight-line basis over the vesting period.
As of December 31, 2015, $1,264 of total unrecognized compensation costs related to restricted stock is expected to be recognized over a weighted-average period of 1.6 years. This amount does not include the cost of new restricted stock that may be granted in future periods.

11.12. Concentration of Credit Risk
We had cash deposits at U.S. banks and financial institutions which exceeded federally insured limits at December 31, 2015.2016. We are exposed to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, we do not anticipate non-performance by these institutions.

12.13. Commitments, Guarantees and Contingencies
Commitments and Guarantees
Our software license agreements include a performance guarantee that our software products will substantially operate as described in the applicable program documentation for a period of 365 days after delivery. To date, we have not incurred any significant costs associated with our performance guarantee or other related warranties and do not expect to incur significant warranty costs in the future. Therefore, no accrual has been made for potential costs associated with these warranties. Certain arrangements also include performance guarantees related to response time, availability for operational use, and other performance-related guarantees. Certain arrangements also include penalties in the form of maintenance credits should the performance of the software fail to meet the performance guarantees. To date, we have not incurred any significant costs associated with these warranties and do not expect to incur significant warranty costs in the future. Therefore, no accrual has been made for potential costs associated with these warranties.
We have historically offered short-term rights of return in certain sales arrangements. If we are able to estimate returns for these types of arrangements and all other criteria for revenue recognition have been met, revenue is recognized and these arrangements are recorded in the consolidated financial statements. If we are unable to estimate returns for these types of arrangements, revenue is not recognized in the consolidated financial statements until the rights of return expire, provided also, that all other criteria of revenue recognition have been met.
Certain standard sales agreements contain a money back guarantee providing for a performance guarantee that is already part of the software license agreement as well as training and support. The money back guarantee also warrants that the software will remain robust and flexible to allow participation in the federal health incentive programs. The specific elements of the performance guarantee pertain to aspects of the software, which we have already tested and confirmed to consistently meet using our existing software without any modifications or enhancements. To date, we have not incurred any costs associated with this guarantee and do not expect to incur significant costs in the future. Therefore, no accrual has been made for potential costs associated with this guarantee.
Our standard sales agreements contain an indemnification provision pursuant to which we shall indemnify, hold harmless, and reimburse the indemnified party for losses suffered or incurred by the indemnified party in connection with any United States patent, any copyright or other intellectual property infringement claim by any third-party with respect to our software. As we have not incurred any significant costs to defend lawsuits or settle claims related to these indemnification agreements, we believe that our estimated exposure on these agreements is currently minimal. Accordingly, we have no liabilities recorded for these indemnification obligations.

19



Hussein Litigation
On October 7, 2013, a complaint was filed against our Company and certain of our officers and directors in the Superior Court of the State of California for the County of Orange, captioned Ahmed D. Hussein v. Sheldon Razin, Steven Plochocki, Quality Systems, Inc. and Does 1-10, inclusive, No. 30-2013-00679600-CU-NP-CJC, by Ahmed Hussein, a former director and significant shareholder of our Company.  We filed a demurrer to the complaint, which the courtCourt granted on April 10, 2014. An amended complaint was filed on April 25, 2014. The amended complaint generally alleges fraud and deceit, constructive fraud, negligent misrepresentation and breach of fiduciary duty in connection with statements made to our shareholders regarding our financial condition and projected future performance. The amended complaint seeks actual damages, exemplary and punitive damages and costs. We filed a demurrer to the amended complaint. On July 29, 2014, the courtCourt sustained the demurrer with respect to the breach of fiduciary duty claim, and overruled the demurrer with respect to the fraud and deceit claims. On August 28, 2014, we filed an answer and also filed a cross-complaint against the plaintiff, alleging that the plaintiff breached fiduciary duties owed to the Company, Mr. Razin and Mr. Plochocki. Mr. Razin and Mr. Plochocki have dismissed their claims against Hussein, leaving QSI as the sole plaintiff in the cross-complaint. On June 26, 2015, we filed a motion for summary judgment, which the courtCourt granted on September 16, 2015, dismissing all claims against us. On September 23, 2015, the plaintiff filed an application for reconsideration of the Court's summary judgment order, which the courtCourt denied. On October 28, 2015, the plaintiff filed a motion for summary judgment, seeking to dismiss our cross-complaint. The hearingcross-complaint, which the Court denied on March 3, 2016. On May 9, 2016, the plaintiff'splaintiff filed a motion for summary adjudication, seeking to again dismiss our cross-complaint, which the Court denied on August 5, 2016. On August 5, 2016, the plaintiff filed a motion for judgment on the pleadings, seeking to again


dismiss our cross-complaint, which the Court denied on September 2, 2016. Trial is set for February 18, 2016.April 10, 2017 on QSI's cross-complaint. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.
Federal Securities Class Action
On November 19, 2013, a putative class action complaint was filed on behalf of the shareholders of our Company other than the defendants against us and certain of our officers and directors in the United States District Court for the Central District of California by one of our shareholders. After the courtCourt appointed lead plaintiffs and lead counsel for this action, and recaptioned the action In re Quality Systems, Inc. Securities Litigation, No. 8L13-cv-01818-CJC(JPRx), lead plaintiffs filed an amended complaint on April 7, 2014. The amended complaint, which is substantially similar to the litigation described above under the caption “Hussein Litigation,” generally alleges that statements made to our shareholders regarding our financial condition and projected future performance were false and misleading in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the individual defendants are liable for such statements because they are controlling persons under Section 20(a) of the Exchange Act. The complaint seeks compensatory damages, court costs and attorneys' fees. We filed a motion to dismiss the amended complaint on June 20, 2014, which the courtCourt granted on October 20, 2014, dismissing the complaint with prejudice. Plaintiffs filed a motion for reconsideration of the Court's order, which the courtCourt denied on January 5, 2015. On January 30, 2015, Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Ninth Circuit, captioned In re Quality Systems, Inc. Securities Litigation, No. 15-55173. Plaintiffs filed their opening brief and we answered. Oral argument is not yet scheduled.was held on December 5, 2016. The Court's decision remains pending. We believe that the plaintiffs' claims are without merit and continue to defend against them vigorously. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.
Shareholder Derivative Litigation
On January 24, 2014, a complaint was filed against our Company and certain of our officers and current and former directors in the United States District Court for the Central District of California, captioned Timothy J. Foss, derivatively on behalf of himself and all others similarly situated, vs. Craig A. Barbarosh, George H. Bristol, James C. Malone, Peter M. Neupert, Morris Panner, D. Russell Pflueger, Steven T. Plochocki, Sheldon Razin, Lance E. Rosenzweig and Quality Systems, Inc., No. SACV14-00110-DOC-JPPx, by Timothy J. Foss, a shareholder of ours. The complaint arises from the same allegations described above under the captions “Hussein Litigation” and “Federal Securities Class Action” and generally alleges breach of fiduciary duties, abuse of control and gross mismanagement by our directors, in addition to unjust enrichment and insider selling by individual directors. The complaint seeks compensatory damages, restitution and disgorgement of all profits, court costs, attorneys’ fees and implementation of enhanced corporate governance procedures. The parties have agreed to stay this litigation until the United States Court of Appeals for the Ninth Circuit issues a ruling on the pending appeal described above under the caption “Federal Securities Class Action”. We believe that the plaintiff’s claims are without merit and intend to defend against them vigorously. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.


13.14. Operating Segment Information
Effective July 1, 2016, we revised our reportable operating segments. As part of December 31, 2015, our Company has three reportableongoing reorganization efforts, we refined the measurement of our segment data to better reflect our current internal organizational structure whereby certain functions that formerly existed within each individual operating segment have changed. Our operating segments that arenow consist of the Software and Related Solutions segment and the RCM and Related Services segment, which is consistent with the disaggregated financial information used and evaluated regularly by our chief operating decision making groupmaker (consisting of our Chief Executive Officer, Interim Chief Financial OfficerOfficer) to assess performance and Chief Operating Officer) in deciding how to allocate resourcesmake decisions about the allocation of resources. Revenue and in assessing performance. The Hospital Solutions Division operatinggross profit are the key measures of segment data for the three and nine months ended December 31, 2015 are reflected through the date of disposition on October 22, 2015.

20



Operating segment data is as follows:
  Three Months Ended December 31, Nine Months Ended December 31,
  2015 2014 2015 2014
Revenues:        
NextGen Division $88,693
 $92,054
 $275,282
 $276,914
RCM Services Division 22,994
 21,913
 67,989
 58,226
QSI Dental Division 4,726
 4,480
 13,825
 13,379
Hospital Solutions Division 619
 4,977
 7,469
 13,318
Consolidated revenue $117,032
 $123,424
 $364,565
 $361,837
         
Income (loss) from operations:  
      
NextGen Division $42,012
 $45,108
 $134,510
 $134,166
RCM Services Division 4,838
 4,681
 13,334
 9,583
QSI Dental Division 1,783
 1,523
 4,369
 3,859
Hospital Solutions Division (2,103) 372
 (927) (2,150)
Corporate and unallocated (38,093) (43,474) (121,319) (122,234)
Consolidated operating income $8,437
 $8,210
 $29,967
 $23,224
The major components of the Corporate and unallocated amounts are summarized in the table below:
  Three Months Ended December 31, Nine Months Ended December 31,
  2015 2014 2015 2014
Research and development costs $14,518
 $18,468
 $49,584
 $51,602
Amortization of capitalized software costs 2,499
 3,073
 7,428
 10,190
Marketing expense 2,925
 3,328
 9,664
 9,439
Other Corporate and overhead costs 18,151
 18,605
 54,643
 51,003
Total Corporate and unallocated 38,093
 43,474
 121,319
 122,234
Assets by segment are not tracked orprofitability used by our chief operating decision making groupmaker to allocate resources or to assessmeasure segment operating performance and thusto make key business decisions. The revenues and gross profit of each segment are derived from distinct product and services within each segment. The Software and Related Solutions segment aggregates the revenues and gross profit of our software-related products and services, including software license and hardware, software-related subscription services, support and maintenance, EDI and data services, and certain professional services, such as implementation, training, and consulting. The RCM and Related Services segment aggregates the revenues and gross profit of our RCM services and certain related ancillary service offerings.
Certain functional roles that do not includedengage in the table above.
The amounts classifiedrevenue generating activities, such as Corporateproduct solutions and unallocated consist primarily ofstrategy, research and development, and certain corporate general and administrative costs, non-recurring acquisition and transaction-related costs, recurring post-acquisition amortization of certain acquired intangible assets and amortization of capitalized software costs, as well as costs of other centrally managed overhead and shared-services functions, including accounting and finance, human resources, marketing, and legal, are considered to be shared-services and research and development, that are not controlled by segment levelsegment-level leadership. Although the segments may derive direct benefits as a result of such costs,shared-services functions, our chief operating decision making groupmaker evaluates performance based upon stand-alone segment revenues and gross profit. Accordingly, the shared-services functions are not considered separate operating income, which excludes these Corporatesegments, and unallocated amounts.
Effective April 1, 2015, as partthe related operating expenses are not included within our operating segments disclosure. Additionally, total assets are managed at a consolidated level and thus are also not included within our operating segments disclosure. Accounting policies for each of our ongoing effortsoperating segments are the same as those applied to refine the measurement of our consolidated financial statements.


Operating segment data to better reflect an organizational structure whereby certain expenses managed by functional area leadership are no longer classified withinfor the operating segments but rather as a component of Corporatethree and unallocated, we no longer classify certain costs within the information servicesnine months ended December 31, 2016 and credit granting and collections functional areas, such as bad debt expense and other information services related general and administrative costs, within the operating segments. Such classification2015 is consistent with the disaggregated financial information used by our chief decision making group. We have retroactively reclassified the prior year operating incomesummarized in the table abovebelow. Prior period data has been retroactively reclassified to present all segment information on a comparable basis. The change in reportable segments has no impact to consolidated revenues and consolidated cost of revenue, nor does it affect our presentation of revenue and cost of revenue on the consolidated statements of comprehensive income.
  Three Months Ended December 31, Nine Months Ended December 31,
  2016 2015 2016 2015
Revenue:        
Software and Related Solutions $106,958
 $93,927
 $312,854
 $291,783
RCM and Related Services 20,910
 22,486
 64,385
 65,313
Hospital Solutions(1)
 
 619
 
 7,469
Consolidated revenue $127,868
 $117,032
 $377,239
 $364,565
         
Gross profit (loss):        
Software and Related Solutions $71,252
 $58,949
 $204,414
 $184,982
RCM and Related Services 7,077
 7,769
 21,337
 20,792
Hospital Solutions(1)
 
 (69) 
 2,569
Unallocated cost of revenue(2)
 (4,813) (3,402) (15,676) (10,138)
Consolidated gross profit $73,516
 $63,247
 $210,075
 $198,205

(1) The former Hospital Solutions Division was divested in October 2015 and therefore, does not represent a distinct operating segment. Historical amounts for Hospital Solutions have not been revised.
(2) Consists of amortization of acquired software technology and amortization of capitalized software costs not allocated to the operating segments for the purposes of measuring performance.

15. Restructuring Plan
In fiscal year 2016, we initiated a three-phase plan intended to better position our organization for future success. We implemented a series of actions with the objective of achieving greater synergies and further integration of our products and services in support of our business strategies, and enabling a more efficient, integrated and client-centered delivery of the holistic solutions that we believe is required by our ambulatory care clients. We also transformed our management team with the appointment of a new chief executive officer, chief financial officer, chief technology officer, chief strategy officer, and chief client officer. In the first phase, we redesigned the organization to more effectively support the execution of our strategy. Under phase two of our reorganization, we will continue to build our infrastructure and enhance our healthcare information technology capabilities to drive future revenue growth. The third phase of the plan will consist of developing and marketing the services and solutions that we believe will accelerate revenue growth.
The overall plan also includes a multi-year initiative, called NextGen 2.0, to merge our business units into a more streamlined, functional-based organization structure and to realign our organizational structure by consolidating the sales, marketing, information services, and software development responsibilities into single, company-wide roles in order to achieve greater efficiency. As a result, our reportable segments have changed and may change again due to such changes in the organization of our business.
The first phase was completed in April 2016, when we announced a corporate restructuring plan, which was approved by our Board of Directors. During the three and nine months ended December 31, 2016, we recorded $231 and $4,685, respectively, of restructuring costs within operating expenses in our consolidated statements of comprehensive income. The restructuring costs consist primarily of payroll-related costs, such as severance, outplacement costs, and continuing healthcare coverage, associated with the involuntary separation of employees pursuant to a one-time benefit arrangement, which were accrued when it was probable that the benefits will be paid and the amount were reasonably estimable. The remaining restructuring liability as of December 31, 2016 was not significant. The restructuring plan is expected to be complete by the end of fiscal 2017.

14. Subsequent Events

On January 4, 2016, we entered into a $250,000 revolving credit agreement (the "Credit Agreement") with JPMorgan Chase Bank, N.A., as administrative agent, U.S. Bank National Association, as syndication agent, and certain other lenders. The initial draw down on the Credit Agreement was approximately $173,509. The Credit Agreement is secured by substantially all of our existing and future property and material domestic subsidiaries. The Credit Agreement provides a subfacility of up to $10,000 for letters of credit and a subfacility of up to $10,000 for swing-line loans. The Credit Agreement matures on January 4, 2021 and the full balance of the revolving loans and all other obligations under the agreement must be paid at that time.

21



The revolving loans under the Credit Agreement bear interest at our option of either, (a) a base rate based on the highest of (i) the rate of interest per annum publicly announced from time to time by JPMorgan Chase Bank, N.A., as its prime rate, (ii) the greater of (A) the federal funds effective rate and (B) the overnight bank funding rate (as determined by the Federal Reserve Bank of New York) plus 0.50% and (iii) the one-month LIBOR plus 1.00%) plus an applicable margin based on our leverage ratio from time to time, ranging from 0.50% to 1.50%, or (b) a LIBOR-based rate (subject to a floor of 0.00%) plus an applicable margin based on our leverage ratio from time to time, ranging from 1.50% to 2.50%. We will also pay a commitment fee of between 0.25% and 0.45%, payable quarterly in arrears, on the average daily unused amount of the revolving facility based on our leverage ratio from time to time.
The revolving loans are subject to customary representations, warranties and ongoing affirmative and negative covenants and agreements. The negative covenants include, among other things, limitations on indebtedness, liens, asset sales, mergers and acquisitions, investments, transactions with affiliates, dividends and other restricted payments, subordinated indebtedness and amendments to subordinated indebtedness documents and sale and leaseback transactions. The Credit Agreement also requires us to maintain a maximum leverage ratio and minimum fixed charge coverage ratio. The revolving loans under the Credit Agreement will be available for letters of credit, working capital and general corporate purposes.
Also on January 4, 2016, we completed our acquisition of HealthFusion Holdings, Inc. ("HealthFusion") pursuant to the Agreement and Plan of Merger (the “Merger Agreement"), dated October 30, 2015. HealthFusion provides Web-based, cloud computing software for physicians, medical billing service providers, and hospitals. Its flagship product, MediTouch, is a fully-integrated, cloud-based software suite consisting of clearinghouse, practice management, electronic health records, and patient portals with rich functionality to enable mobility, workflow automation, and advanced reporting and analytics aimed primarily at small-to-mid-size physician practices. The acquisition of HealthFusion is part of our strategy to expand its client base and cloud-based solution capabilities in the ambulatory market. Over time, we plan to expand the HealthFusion platform to satisfy the needs of practices of increasing size and complexity.
Total cash consideration paid was $165,000, subject to certain adjustments in accordance with the Merger Agreement. In addition, we may pay up to an additional $25,000 in cash in the form of an earnout, subject to HealthFusion achieving certain revenue targets through December 31, 2016. This acquisition was funded by our initial draw down of the Credit Agreement, a portion of which has been subsequently repaid from our cash on hand. We are in the process of determining the purchase price allocation for this acquisition.

22



Item 2.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q ("Report") and certain information incorporated herein by reference contain forward-looking statements within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Quarterly Report, on Form 10-Q, other than statements that are purely historical, are forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “should,” “would,” “could,” “may,” and similar expressions also identify forward-looking statements. These forward-looking statements include, without limitation, discussions of our product development plans, business strategies, future operations, financial condition and prospects, developments in and the impacts of government regulation and legislation, including, without limitation, The American Recovery and Reinvestment Act, ("ARRA"), the Patient Protection and Affordable Care Act, ("PPACA"), and the Medicare Access and CHIP Reauthorization Act of 2015, ("MACRA"), and market factors influencing our results. Our expectations, beliefs, objectives, intentions and strategies regarding our future results are not guarantees of future performance and are subject to risks and uncertainties, both foreseen and unforeseen, that could cause actual results to differ materially from results contemplated in our forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to continue to develop new products and increase systems sales in markets characterized by rapid technological evolution, consolidation, and competition from larger, better-capitalized competitors. Many other economic, competitive, governmental and technological factors could affect our ability to achieve our goals, and interested persons are urged to review any risks that may be described in “Item 1A. Risk Factors” as set forth herein and other risk factors appearing in our most recent Annual Report on Form 10-K for the fiscal year ended March 31, 20152016 (“Annual Report”), as supplemented by additional risk factors, if any, in our interim filings on our Quarterly Reports on Form 10-Q, as well as in our other public disclosures and filings with the Securities and Exchange Commission ("SEC"). Because of these risk factors, as well as other variables affecting our financial condition and results of operations, past financial performance may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods. We assume no obligation to update any forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of the filing of this Quarterly Report on Form 10-Q.Report.
This management's discussion and analysis of financial condition and results of operations ("MD&A") is provided as a supplement to the consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q in order to enhance your understanding of our results of operations and financial condition and should be read in conjunction with, and is qualified in its entirety by, the consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q.Report. Historical results of operations, percentage margin fluctuations and any trends that may be inferred from the discussion below are not necessarily indicative of the operating results for any future period.
Our MD&A is organized as follows:
Management Overview. This section provides a general description of our Company and operating segments, a discussion as to how we derive our revenue, background information on certain trends and developments affecting our Company and a discussion on management’s strategy for driving revenue growth.
Critical Accounting Policies and Estimates. This section discusses those accounting policies that are considered important to the evaluation and reporting of our financial condition and results of operations, and whose application requires us to exercise subjective or complex judgments in making estimates and assumptions. In addition, all of our significant accounting policies, including our critical accounting policies, are summarized in Note 1, “Summary of Significant Accounting Policies,” of our notes to consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Company Overview.  This section provides a more detailed description of our Company, its operating segments, a summary of our recent acquisition transactions and the products and services we offer.
Overview of Results of Operations and Results of Operations by Divisions. These sections provide our analysis and outlook for the significant line items on our consolidated statements of comprehensive income, as well as other information that we deem meaningful to understand our results of operations on both a consolidated basis and divisional basis.
Liquidity and Capital Resources.  This section provides an analysis of our liquidity and cash flows.
New Accounting Pronouncements. This section provides a summary of the most recent authoritative accounting standards and guidance that have either been recently adopted by our Company or may be adopted in the future.

23



Management Overview
Quality Systems, Inc., primarily through its NextGen Healthcare subsidiary, provides technology-based solutions and its wholly-owned subsidiaries operate as three business divisions (each, a "Division") which are comprised of: (i)services to the NextGen Division, (ii) the RCM Services Division, and (iii) the QSI Dental Division. The Hospital Solutions Division was sold to QuadraMed Affinity Corporation (part of the Harris Operating Group of Constellation Software Inc.) on October 22, 2015. We also have a captive entity in India called Quality Systems India Healthcare Private Limited (“QSIH”).
We primarily derive revenue by developing and marketing healthcare information systems that automate certain aspects of medical and dental practices, networks of practices such as physician hospital organizations (“PHOs”) and management service organizations (“MSOs”), accountable care organizations, ambulatory care centers, community health centers and medical and dental schools along with comprehensive systems implementation, maintenance and support and add-on complementary services such as revenue cycle management (“RCM”) and electronic data interchange (“EDI”).market in the United States. Our systems and servicessolutions provide our customersclients with the ability to redesign patient care and other workflow processes while improving productivity through the facilitation of managed access to patient information. UtilizingWe help promote healthy communities by empowering physician practice success and enriching the patient care experience while lowering the cost of healthcare.
We primarily derive revenue by developing and marketing software and services that automate certain aspects of practice management (“PM”) and electronic health records (“EHR”) for medical and dental practices. Our software can be licensed on a perpetual, on-premise basis, hosted in a private cloud or, in certain instances, as a software-as-a-service (“SaaS”) solution. We market and sell our proprietarysolutions through a dedicated sales force and to a much lesser extent, through resellers. Our clients include single and small practice physicians, networks of practices such as physician hospital organizations (“PHOs”), management service organizations (“MSOs”), accountable care organizations (“ACOs”), ambulatory care centers, community health centers and medical and dental schools. We also provide implementation, training, support and maintenance for software in combination with third party hardware and software solutions, our products enablecomplementary services such as revenue cycle management (“RCM”) and electronic data interchange (“EDI”).
We have a history of developing new and enhanced technologies. Over the integrationcourse of a varietynumber of administrativeyears, we have also made strategic acquisitions to complement and clinical information operations. Our scalable interoperability and population health offerings help to improve care collaboration, quality and safety. Enabled byenhance our interoperability and enterprise analytics solutions, data-driven patient population healthcare management decisions can assist in creating more desirable operational, clinical, and financial outcomes that substantiate the value of patient-centered and accountable care models.
The turbulenceproduct portfolio in the worldwide economy has impacted almost all industries. Whileambulatory care, RCM, and hospital markets.
Quality Systems, Inc. was incorporated in California in 1974. Our principal offices are located at 18111 Von Karman Ave., Suite 800, Irvine, California, 92612. Our websites are located at www.nextgen.com and www.qsii.com. We operate on a fiscal year ending on March 31.
Trends and Events in Our Business
We believe that the following trends and events as described below have contributed to our consolidated results of operations and may continue to impact our future results.


We believe healthcare is not immune to economic cycles, we believe it is more heavily influenced by U.S.-based regulatory and national health projects than by the cycles of our economy. The impact of the current economic conditions on our existing and prospective customers has been mixed. Various factors have had, and are anticipated to continue to have, a meaningful impact on the U.S. healthcare industry. Particularly, the healthcare industry has been significantly impacted by the Obama Administration's broad healthcare reform efforts, including the Health Information Technology for Economic and Clinical Health ("HITECH") portion of the American Recovery and Reinvestment Act of 2009 ("ARRA"HITECH Act") and the Patient Protection and Affordable Care Act ("PPACA"ACA") that providesprovided significant incentives to health care organizations for "Meaningful Use" adoption and interoperable electronic health record solutions, the mandate requiring individuals to obtain insurance, the individual state responses to the government-requested Medicaid expansion, the creation and operation of insurance exchanges, and the increasing focus of private businesses on moving their employee health benefit offerings to a more wellness-based health platform.solutions.
We have benefited and hope to continue to benefit from the increased demands on healthcare providers for greater efficiency and lower costs, financial incentives from the HITECH portion of the ARRA to physicians who adopt electronic health records, as well as increased adoption rates for electronic health records and other technology in the healthcare arena. We also believe that healthcare reform, including the repeal of the sustainable growth rate (SGR)("SGR") formula in April 2015 as part of the Medicare Access and CHIP Reauthorization Act of 2015 ("MACRA"), and a movement towards a value-based, pay for performancepay-for-performance model and quality initiative efforts will also stimulate demand for robust electronic health record solutions as well as new healthcarehealth information technology solutions from bundled billing capabilities to patient engagement and population health management. We believe MACRA may be the most important of the three regulations for our market because it permanently changes how ambulatory healthcare providers are reimbursed by Medicare. It offers certainty and a timeline for the market’s move away from volume-based, fee-for-service models to value-based payment models that reward the delivery of lower cost, high quality care.
While we expect to benefit from the increasing demands for greater efficiency as well as government support for increased adoption of electronic health records, systems, the market for physician based electronic health records software is becoming increasingly saturated while physician group practices are rapidly being consolidated by hospital,hospitals, insurance payers and other entities. Hospital software providers are leveraging their position with their hospital customersclients to gain market share with hospital owned physician practices. Insurance providers and large physician groups are also consolidating physician offices creating additional opportunity for ambulatory software providers like us. Our strategy is to focus on addressing the growing needs of accountable care organizations around interoperability, patient engagements, population health, and collaborative care management, and data analytics.
We believe that our core strength lies in the central role our software products and services play in the delivery of healthcare by the primary physician in an ambulatory setting. We intend to remain at the forefront of upcoming new regulatory requirements includingand meaningful use requirements for stimulus payments. We believe that the expanded requirements for continued eligibility for incentive payments under meaningful use rules will result in an expanded replacement market for electronic health records software. We intend to continue the development and enhancement of our software solutions to support healthcare reform, such as the recently enacted MACRA, which promotes the transition from fee-for-service to value-based, pay-for-performance and patient-centric care and quality initiatives such as accountable care organizations. Key elements of our future software development will be to expand our interoperability capabilities enhancing the competitiveness of our software offerings, make our products more intuitive and easy to use, and to enhance the capability of our abilityMediTouch® Platform to allow us to deliver our software over the cloud to larger ambulatory care practices.
In addition to the activities described above, mergers and acquisitions have been important to our development. In September 2013 we acquired Mirth Corporation ("Mirth"), a global leader in health information technology that helps clients achieve interoperability. In April 2015, we acquired Gennius, Inc. ("Gennius"), a population health analytics company which we believe enhances and leverages our acquisition of Mirth by broadening our business intelligence capabilities in the growing population health and value based care areas. In January 2016, we completed the acquisition of HealthFusion Holdings, Inc. ("HealthFusion"), a cloud-based healthcare information technology (“HCIT”) company providing electronic health record (“EHR”) and practice management (“PM”) software primarily to the one-to-ten physician size market. We entered into a revolving credit agreement to fund the transaction. We believe the acquisition provided us with access to a market we were not in and provides us with technology that will accelerate our transition to the cloud.
We continue to evaluate the organizational structure of our company with the latest technology.objective of achieving greater synergies and further integration of our products and services, in support of our business strategies. In fiscal 2016, we initiated a three-phase plan to better position our organization for future success. In the first phase, we redesigned the organization to more effectively support the execution of our strategy. We also transformed our management team with the appointment of a new chief executive officer, chief financial officer, chief technology officer, chief strategy officer, and chief client officer. This first phase was completed in April 2016, when we announced a corporate restructuring plan intended to enable a more efficient, integrated and client-centered delivery of the holistic solutions that we believe is required by our ambulatory care clients. The restructuring plan includes merging our business units into a more streamlined, functional-based organization structure. We are now beginning phase two of our reorganization, which includes building and enhancing the capabilities that will drive future revenue growth. The third phase of the plan will consist of developing and marketing the services and solutions that we believe will accelerate revenue growth.
We also wanthave made and intend to continue making substantial investments in our infrastructure includingwhile continuing our strong commitment of service in support of our client satisfaction programs and maintaining reasonable expense discipline. Such investments include but are not limited to maintaining and expanding sales, marketing and product development activities in order to improve patient care and reduce healthcare costs, providing industry-leading, integrated clinical and administrative healthcare data systems, services, and expertise to clinical, medical, technology, and healthcare business professionals while continuing our strong commitment of superb service in support of our customer satisfaction programs. These investments in our infrastructure will continue while maintaining reasonable expense discipline.professionals. We also strive to add new customersclients and expand our relationship with existing customersclients through delivery of add-on and complementary products and

24



services and services. We believe that our customerthe client base that is usinguses our software on a daily basis is a strategic asset. Weasset, and we intend to leverage this strategic asset by expanding our product and service offerings towards this customerclient base.
On January 4, 2016,Led by our vision and mission, we completedare resetting our strategy and structure to deliver value to our clients. To achieve lower-cost, increased structural capability, our new management team is building an aligned, client-focused organization, supported by a recurring revenue stream and a large and diverse existing client base.


Our Strategy
We strive to be the trusted partner for clients of all size, integrating services, software and analytics into a consolidated solution. As a healthcare information technology and services company, we plan to continue investing in our current capabilities as well as building and/or acquiring new capabilities as we guide our clients from fee-for-service to fee-for-value payer reimbursement models. With approximately 90,000 providers using our solutions, we are enabling care and believe we can truly transform the delivery of care through the following strategic priorities:
Focus on the ambulatory client segment. In October 2015, we sold our Hospital Solutions Division to focus on our core ambulatory clients. Further, a recent operational reorganization better allows us to serve the needs of our ambulatory clients through a simpler, more nimble, and focused organization. We believe it is essential to protect, build and sell new capabilities within our ambulatory platform. We are focused on our core by increasing quality and the serviceability of our solutions. We intend to continue to enhance the capabilities of our NextGen Ambulatory flagship product.
Cloud transition. Through our acquisition of HealthFusion Holdings, Inc. ("HealthFusion") pursuant toin January 2016, we acquired a highly scalable, pure cloud-based and mobile-enabled platform that operates under the Agreement and Plan of Merger, dated October 30, 2015. HealthFusion provides Web-based, cloud computing software for physicians, medical billing service providers, and hospitals. Its flagship product, MediTouch, is a fully-integrated, cloud-based software suite consisting of clearinghouse, practice management, electronic health records, and patient portals with rich functionality to enable mobility, workflow automation, and advanced reporting and analytics aimed primarily at small-to-mid-size physician practices. The acquisition of HealthFusion is part of our strategy to expand its client base and cloud-based solution capabilities in the ambulatory market. Over time, we plantradename MediTouch®. We intend to expand the HealthFusioncapability of this platform to satisfyserve the needsrequirements of practiceslarger ambulatory practices. When combined with our Mirth-branded products, we can offer our clients a full suite of increasing sizecloud-based solutions that better enable our clients to focus on care delivery.
Solutions selling. We believe there is significant opportunity to extend the solutions we offer existing and complexity.new clients through value added services such as RCM, EDI, interoperability solutions and professional services. This will evolve our relationships from being a seller of products and services to delivering a consistent solution suite and experience for our clients.
Population health software and services. We are evaluatingmigrating into applications, analytics and services that we believe will enable our clients to be successful in managing the impacthealth of HealthFusion’s existing cloud-based product onpatient populations. We are establishing strong development partners within our ongoing efforts to developcore client base, participating in shared-risk contracts, and release our NextGen Now cloud-based platform. Our assessment may lead usworking together to determine thatpopulation health solutions.
More effective use of capital. From cessation of the HealthFusion product, which is already a production-ready and sellable solution, may representdividend, leveraging our balance sheet for future opportunities, to managing our cost structure, we are transforming our capital strategy. Our recent reorganization was formulated to result in a more prudent investment in our technical future than continuing with the NextGen Now development plans. If we decide to abandon further development of the previously capitalized NextGen Now platform or certain components thereof, a material impairment of the asset may result.efficient, integrated and streamlined organization.
Critical Accounting Policiesand Estimates
The discussion and analysis of our consolidated financial statements and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.America ("GAAP"). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect theour reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an on-going basis, we evaluate estimates (including but not limited to those related to revenue recognition, accounts receivable reserves, software development costs, contingent consideration liabilities, goodwill, and intangible assets) for reasonableness.disclosures. We base our assumptions, estimates and judgments on historical experience, current trends, and on various other assumptions that management believesfactors we believe to be reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. On a regular basis, we review the results of which form the basis for makingaccounting policies and update our assumptions, estimates, and judgments, about the carrying values of assetsas needed, to ensure that our consolidated financial statements are presented fairly and liabilities that may not be readily apparent from other sources.in accordance with GAAP. Actual results maycould differ materially from theseour estimates under different assumptions or conditions. To the extent that there are material differences between our estimates and actual results, our financial condition or results of operations will be affected.
We describe our significant accounting policies in Note 2, “Summary of Significant Accounting Policies,” of our notes to consolidated financial statements included in our Annual Report. We discuss our critical accounting policies and estimates in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report. There have been no material changes in our significant accounting policies or critical accounting policies and estimates since the endfiscal year ended March 31, 2016.



Results of Operations
The following table sets forth the percentage of revenue represented by each item in our consolidated statements of comprehensive income for the three and nine months ended December 31, 2016 and 2015 (certain percentages below may not sum due to rounding):
 Three Months Ended December 31, Nine Months Ended December 31,
 2016 2015 2016 2015
Revenues:       
Software license and hardware13.3% 13.8% 13.0% 14.3%
Software related subscription services17.6
 10.0
 16.9
 10.0
Total software, hardware and related30.9
 23.8
 29.9
 24.3
Support and maintenance31.2
 33.8
 31.0
 34.4
Revenue cycle management and related services15.7
 18.5
 16.4
 17.2
Electronic data interchange and data services17.0
 17.6
 17.4
 16.8
Professional services5.1
 6.3
 5.3
 7.3
Total revenues100.0
 100.0
 100.0
 100.0
Cost of revenue:       
Software license and hardware4.4
 5.6
 5.1
 5.5
Software related subscription services7.3
 4.7
 7.2
 4.8
Total software, hardware and related11.8
 10.3
 12.3
 10.3
Support and maintenance5.7
 6.4
 5.5
 6.5
Revenue cycle management and related services10.5
 12.3
 11.1
 12.0
Electronic data interchange and data services9.9
 10.6
 10.1
 10.2
Professional services4.6
 6.3
 5.2
 6.6
Total cost of revenue42.5
 46.0
 44.3
 45.6
Gross profit57.5
 54.0
 55.7
 54.4
Operating expenses:       
Selling, general and administrative29.4
 33.7
 32.1
 31.8
Research and development costs, net15.4
 12.4
 14.9
 13.6
Amortization of acquired intangible assets2.0
 0.8
 2.1
 0.7
Restructuring costs0.2
 
 1.2
 
Total operating expenses47.0
 46.8
 50.3
 46.1
Income from operations10.5
 7.2
 5.4
 8.2
Interest income
 0.1
 
 0.1
Interest expense(0.5) 
 (0.6) 
Other expense, net
 
 
 
Income before provision for income taxes10.0
 7.2
 4.7
 8.3
Provision for income taxes1.8
 1.0
 1.0
 2.3
Net income8.2% 6.2% 3.7% 6.0%




Revenues
The following table presents our consolidated revenues for the three and nine months ended December 31, 2016 and 2015 (in thousands):
 Three Months Ended December 31, Nine Months Ended December 31,
 2016 2015 2016 2015
Revenues:       
Software license and hardware$16,995
 $16,150
 $48,966
 $52,026
Software related subscription services22,546
 11,705
 63,911
 36,388
Total software, hardware and related39,541
 27,855
 112,877
 88,414
        
Support and maintenance39,924
 39,519
 116,905
 125,408
Revenue cycle management and related services20,048
 21,594
 62,037
 62,630
Electronic data interchange and data services21,790
 20,643
 65,527
 61,413
Professional services6,565
 7,421
 19,893
 26,700
Total revenues$127,868
 $117,032
 $377,239
 $364,565
We generate revenue from sales of licensing rights and subscriptions to our software products, hardware and third party software products, support and maintenance services, revenue cycle management and related services ("RCM"), electronic data interchange and data services (“EDI”), and professional services, such as implementation, training, and consulting performed for clients who use our products.
Consolidated revenue for the three months ended December 31, 2016 increased $10.8 million compared to the prior year period, which was driven primarily by subscription sales of the MediTouch® cloud-based system acquired from HealthFusion in January 2016 and lower level of sales credits and related reserves, which were partially offset by lower RCM revenue due to lower net new bookings.
Consolidated revenue for the nine months ended December 31, 2016 increased $12.7 million compared to the prior year period as a result of $27.5 million higher subscriptions related mostly to sales of the MediTouch® cloud-based system, partially offset by lower software license and hardware revenue, lower professional services revenue, and lower support and maintenance revenue. The decline in software license and hardware revenue was mostly caused by a shift in market dynamics toward cloud-based solutions and away from perpetual license arrangements, which has also resulted in lower demand for our professional services, including implementation, training, and consulting services. The decline in support and maintenance is due primarily to the disposition of the former Hospital Solutions Division in October 2015 and net attrition in products sold with accompanying maintenance.
RCM revenue decreased $1.5 million and $0.6 million for the three and nine months ended December 31, 2016 and 2015, respectively, due to lower net new bookings. EDI revenue increased $1.1 million and $4.1 million for the three and nine months ended December 31, 2016 and 2015, respectively, due to addition of new clients and further penetration of our existing client base.
Recurring service revenue, consisting of software related subscription services, support and maintenance, RCM, and EDI, represented 81.6% and 79.9% of total revenue for the three months ended December 31, 2016 and 2015, respectively. For the nine months ended December 31, 2016 and 2015, recurring service revenue represented 81.7% and 78.4%, respectively, of total revenue.
We expect to benefit from the growth of a replacement market driven by an expected consolidation of electronic health records vendors. We also anticipate the creation of new opportunities in connection with the evolution of healthcare from a fee-for-services reimbursement model to a pay-for-performance model around the management of patient populations. Our acquisitions of Gennius and Mirth provided us with new products and services around population health, collaborative care management, interoperability and enterprise analytics to address these market dynamics. While it remains difficult to assess the relative impact or the timing of positive and negative trends affecting the aforementioned market opportunities, we believe we are well positioned to remain a leader in serving the evolving market needs for healthcare information technology.


Gross Profit
The following table presents our consolidated cost of revenue and gross profit for the three and nine months ended December 31, 2016 and 2015 (in thousands):
 Three Months Ended December 31, Nine Months Ended December 31,
 2016 2015 2016 2015
Total cost of revenue$54,352
 $53,785
 $167,164
 $166,360
Gross profit73,516
 63,247
 210,075
 198,205
Gross margin %57.5% 54.0% 55.7% 54.4%
Cost of revenue consists primarily of compensation expense, including share-based compensation, for personnel that deliver our products and services. Cost of revenue also includes amortization of capitalized software costs and acquired technology, third party consultant and outsourcing costs, costs associated with our EDI business partners and clearinghouses, hosting service costs, third party software costs and royalties, and other costs directly associated with delivering our products and services. Refer to Note 5, "Intangible Assets" and Note 6, "Capitalized Software Costs" of our notes to consolidated financial statements included elsewhere in this Report for additional information on current period amortization of capitalized software costs and acquired technology and an estimate of future expected amortization.
Share-based compensation expense included in cost of revenue was $0.1 million and $0.1 million for the three months ended December 31, 2016 and 2015, respectively, and is included in the amounts in the table above. Share-based compensation expense included in cost of revenue was $0.5 million and $0.3 million for the nine months ended December 31, 2016 and 2015, respectively, and is included in the amounts in the table above.
Gross profit for the three months ended December 31, 2016 increased $10.3 million compared to the prior year period due primarily to higher revenues as discussed above and a lower level of sales credits and related reserves, which were offset by a $0.6 million increase in cost of revenue. Cost of revenue increased due to amortization of the software technology intangible asset acquired from HealthFusion, partially offset by lower amortization of previously capitalized software development costs and lower payroll costs associated with delivering support and maintenance and professional services. The gross margin percentage increased to 57.5% for the three months ended December 31, 2016 compared to 54.0% in the prior year period.
Gross profit for the nine months ended December 31, 2016 increased $11.9 million compared to the prior year period due also to higher revenues as discussed above, offset by a $0.8 million increase in cost of revenue. Cost of revenue increased due to amortization of the software technology intangible asset acquired from HealthFusion, partially offset by lower payroll costs associated with delivering support and maintenance and professional services. The gross margin percentage increased to 55.7% for the nine months ended December 31, 2016 compared to 54.4% in the prior year period.
Selling, General and Administrative Expense
The following table presents our consolidated selling, general and administrative expense for the three and nine months ended December 31, 2016 and 2015 (in thousands):
 Three Months Ended December 31, Nine Months Ended December 31,
 2016 2015 2016 2015
Selling, general and administrative$37,542
 $39,395
 $120,913
 $115,962
Selling, general and administrative, as a percentage of revenue29.4% 33.7% 32.1% 31.8%
Selling, general and administrative expense consist of compensation expense, including share-based compensation, for management and administrative personnel, selling and marketing expense, facilities costs, depreciation, professional service fees, including legal and accounting services, acquisition and transaction-related costs, and other general corporate and administrative expenses.
Share-based compensation expense included in selling, general and administrative expenses was $1.6 million and $0.6 million for the three months ended December 31, 2016 and 2015, respectively, and is included in the amounts in the table above. Share-based compensation expense included in selling, general and administrative expenses was $4.0 million and $1.7 million for the nine months ended December 31, 2016 and 2015, respectively, and is included in the amounts in the table above.
Selling, general and administrative expenses decreased $1.9 million for the three months ended December 31, 2016 compared to the prior year period primarily because we incurred $3.7 million of acquisition-related costs related to the acquisition of HealthFusion in the prior year period, a $1.8 million loss on the disposition of the former Hospital Solutions Division in the prior year period, and recorded a current period benefit of $2.0 million related to fair value adjustments of the HealthFusion contingent


consideration, which were partially offset by higher legal expense related shareholder litigation and additional selling, general and administrative expense associated with the acquisition of HealthFusion.
Selling, general and administrative expenses increased $5.0 million for the nine months ended December 31, 2016 compared to the prior year period primarily due to $3.4 million of fair value adjustments of the HealthFusion contingent consideration recorded in the current period, higher legal expense related shareholder litigation, and additional selling, general and administrative expense associated with the acquisition of HealthFusion, partially offset by lower payroll costs associated with the corporate restructuring plan (refer to Note 15, "Restructuring Plan" of our notes to consolidated financial statements included elsewhere in this Report for additional information) and the disposition of the Hospital Solutions Division in October 2015.
Research and Development Costs, net
The following table presents our consolidated net research and development costs, capitalized software costs, and gross expenditures prior to capitalization, for the three and nine months ended December 31, 2016 and 2015 (in thousands):
 Three Months Ended December 31, Nine Months Ended December 31,
 2016 2015 2016 2015
Gross expenditures$20,766
 $19,435
 $62,601
 $61,188
Capitalized software costs(1,052) (4,917) (6,371) (11,604)
Research and development costs, net$19,714
 $14,518
 $56,230
 $49,584
        
Research and development costs, as a percentage of revenue15.4% 12.4% 14.9% 13.6%
Capitalized software costs as a percentage of gross expenditures5.1% 25.3% 10.2% 19.0%
Gross research and development expenditures, including costs expensed and costs capitalized, consist of compensation expense, including share-based compensation, for research and development personnel, certain third-party consultant fees, software maintenance costs, and other costs related to new product development and enhancement to our existing products. We intend to continue to invest heavily in research and development expenses as we continue to bring additional functionality and features to the medical community and develop a new integrated inpatient and outpatient, web-based software platform.
The capitalization of software development costs results in a reduction to our reported net research and development costs. Our software capitalization rate, or capitalized software costs as a percentage of gross expenditures, has varied historically and may continue to vary based on the nature and status of specific projects and initiatives in progress. Although changes in software capitalization rates have no impact on our overall cash flows, it results in fluctuations in the amount of software development costs being expensed up front and the amount of net research and development costs reported in our consolidated statement of comprehensive income.
Share-based compensation expense included in research and development costs was $0.3 million and $0.1 million for the three months ended December 31, 2016 and 2015, respectively, and is included in the amounts in the table above. Share-based compensation expense included in research and development costs was $0.7 million and $0.3 million for the nine months ended December 31, 2016 and 2015, respectively, and is included in the amounts in the table above.
Net research and development costs for the three months ended December 31, 2016 increased $5.2 million compared to the prior year period primarily as a result of a $3.9 million decline in capitalized software costs and a $1.3 million increase in our gross expenditures. Net research and development costs for the nine months ended December 31, 2016 increased $6.6 million compared to the prior year period primarily as a result of a $5.2 million decline in capitalized software costs and a $1.4 million increase in our gross expenditures. The acquisition of HealthFusion contributed $1.2 million and $2.8 million of net research and development costs for the three and nine months ended December 31, 2016, respectively. Such increase was partially offset by lower gross expenditures from the discontinuation of the NextGen Now development project during the fourth quarter of fiscal year 2015.2016 and lower personnel costs associated with the restructuring plan.
Company Overview
Quality Systems, Inc. was incorporatedThe reduction in Californiacapitalized software costs for the three and nine months ended December 31, 2016 is due to a decline in 1974. Our principal offices are located at 18111 Von Karman Ave., Suite 700, Irvine, California, 92612. We operate on a fiscal year ending on March 31.
Our Company was founded with an early focus on providing information systems to dental group practices. This focus area would later become the QSI Dental Division. In the mid-1980s, we capitalized on the increasing focus on medical cost containment and further expanded our information processing systems to serve the ambulatory market. In the mid-1990s, we made two acquisitions that accelerated our penetrationrate of the ambulatory marketsoftware capitalization compared to the prior year periods, which reflects differences in the nature and formedstatus of our projects and initiatives during a given period that affects the basisamount of development costs that may be capitalized, the discontinuation of the NextGen Now development project, and the recent releases of the next major version of our core software products.


Amortization of Acquired Intangible Assets
The following table presents our amortization of acquired intangible assets for the NextGen Division. Inthree and nine months ended December 31, 2016 and 2015 (in thousands):
 Three Months Ended December 31, Nine Months Ended December 31,
 2016 2015 2016 2015
Amortization of acquired intangible assets$2,568
 $897
 $7,889
 $2,692
Amortization of acquired intangible assets included in operating expense consist of the last few years, weamortization related to our customer relationships, trade name, and contracts intangible assets acquired ViaTrack Systems, LLC ("ViaTrack") and Matrix Management Solutions, LLC ("Matrix") as part of our strategybusiness combinations. Refer to enhanceNote 5, "Intangible Assets" of our EDInotes to consolidated financial statements included elsewhere in this Report for an estimate of future expected amortization.
Amortization of acquired intangible assets for the three and RCM services capabilities. More recently,nine months ended December 31, 2016 increased $1.7 million and $5.2 million, respectively, compared to the prior year periods due to additional amortization of the customer relationships and trade name intangible assets related to the acquisition of HealthFusion. Refer to Note 5, "Business Combinations" of our notes to consolidated financial statements included elsewhere in this Report for additional information.
Restructuring Costs
During the three and nine months ended December 31, 2016, we acquired Mirth Corporation ("Mirth")recorded $0.2 million and Gennius, Inc ("Gennius"), both$4.7 million, respectively, of which operate underrestructuring costs within operating expenses in our consolidated statements of comprehensive income. The restructuring costs resulted from a restructuring plan that we announced in April 2016, and such costs consist primarily of payroll-related costs, such as severance, outplacement costs, and continuing healthcare coverage, associated with the NextGen Division. Mirth enhances our current enterprise interoperability initiatives and broadens our accountable and collaborative care, population health, disease management and clinical data exchange offerings. Genniusinvoluntary separation of employees pursuant to a one-time benefit arrangement. The remaining restructuring liability as of December 31, 2016 was not significant. The restructuring plan is expected to be complete by the end of fiscal 2017.
The restructuring is part of a three-phase plan initiated in fiscal year 2016 that was intended to better position our organization for future success. In the first phase, we restructured the organization to more effectively support the execution of our strategy. We believe that the restructuring will reduce our costs and improve our financial performance. As we begin phase two of our reorganization, we will continue to build our infrastructure and enhance our current enterprise healthcare data analytics competencies while broadening business intelligenceinformation technology capabilities for addressing new value-based care requirements. In October 2015, we sold our Hospital Solutions Division in an effort to focus on our core ambulatory business. Today, we servedrive future revenue growth. The third phase of the ambulatory, RCMplan will consist of developing and marketing the services and dental markets through each ofsolutions that we believe will accelerate revenue growth.
The overall plan also includes a multi-year initiative, called NextGen 2.0, to merge our three business Divisions.
A growing number of customers are simultaneously utilizing software or services from more than one of our Divisions. In an effort to further enhance our ability to cross sell products and services between Divisions, we are in the process of further integrating our products to provideunits into a more robuststreamlined, functional-based organization structure and comprehensive platform to offerrealign our customers. To achieve greater efficiency and integration within our operations, we have consolidated our divisionalorganizational structure by consolidating the sales, marketing, information services, and software development responsibilities into single, company-wide roles. The Divisions also share the resourcesroles in order to achieve greater efficiency.
Refer to Note 15, "Restructuring Plan" of our “corporate office,” which includes a variety of accountingnotes to consolidated financial statements included elsewhere in this Report for additional information.
Interest and other administrative functions. We continue to evaluate the organizational structure of the Company with the objective of achieving greater synergiesOther Income and further integration of our products and services, including software implementation and customer support functions.Expense
The NextGen Division and QSI Dental Division develop and market software that is designed to automate and streamline a number of the administrative functions required for operating a medical or dental, such as patient scheduling and billing. Since practice management software systems have already been implemented by the vast majority of both the medical and dental practices, we actively compete in a replacement market by leveraging the benefits of our interoperable electronic health records software. With

25



the addition of Gennius and Mirth, our combined solutions enrich the already strong collaborative, connected care support and set the stage for data synchronization and enterprise analytics, interoperability growth and expansion of our current accountable and collaborative care, population health, disease management and clinical data exchange offering. These Divisions also develop and market software that automates patient records in physician practices, community health centers and hospital settings. In this patient records area of our business, we are typically competing to replace paper-based patient record alternatives as opposed to replacing previously purchased systems. The RCM Services Division provides technology solutions and outsourcing services to cover the full spectrum of healthcare providers' RCM needs, with a primary focus on outsourced billing and collection services.
QSIH, located in Bangalore, India, functions as our India-based captive entity to offshore technology application development and business processing services. Our employee base in Bangalore has grown to over 450 employees with a primary focus on software development activities.
We continue to pursue product and service enhancement initiatives within each of our Divisions. The majority of such expenditures are currently targeted to the product lines and customer base of the NextGen Division.
The following table reflectspresents our reported segment revenue breakdown by Division and segment revenue growth (decline) as compared to the prior year periodinterest expense for the three and nine months ended December 31, 20152016 and 2014. Operating results for the Hospital Solutions Division are included in the table below through the date of disposition.2015 (in thousands):
  Segment Revenue Breakdown
  Three Months Ended December 31, Nine Months Ended December 31,
  2015 2014 2015 2014
NextGen Division 75.9% 74.6% 75.6% 76.5%
RCM Services Division 19.6% 17.8% 18.6% 16.1%
QSI Dental Division 4.0% 3.6% 3.8% 3.7%
Hospital Solutions Division 0.5% 4.0% 2.0% 3.7%
Consolidated 100.0% 100.0% 100.0% 100.0%
 Three Months Ended December 31, Nine Months Ended December 31,
 2016 2015 2016 2015
Interest income$
 $60
 $9
 $406
Interest expense(629) (11) (2,445) (14)
Other expense, net(4) (43) (146) (147)
  Segment Revenue Growth (Decline)
  Three Months Ended December 31, Nine Months Ended December 31,
  2015 2014 2015 2014
NextGen Division (3.7)% 8.7 % (0.6)% 66.6%
RCM Services Division 4.9 % 30.9 % 16.8 % 70.7%
QSI Dental Division 5.5 % (8.6)% 3.3 % 33.1%
Hospital Solutions Division (87.6)% 5.1 % (43.9)% 30.6%
Consolidated (5.2)% 11.1 % 0.8 % 64.0%
NextGen Division. The NextGen Division, with headquarters in Horsham, Pennsylvania and significant locations in Atlanta, Georgia and Costa Mesa, California, provides integrated clinical, financial and connectivity solutions for ambulatory and dental provider organizations. The NextGen Division's major product categories include the NextGen® ambulatory product suite and interoperability solutions.
The NextGen® ambulatory product suite features an integrated and interoperable solution that streamlines the business of running a practice as well as patient care with standardized, real-time clinical and administrative workflows within a physician’s practice. Major ambulatory product lines include NextGen® EHR ("Electronic Health Record"), NextGen® PM ("Practice Management"), NextGen® Population Health (including NextGen® Care), NextGen® Analytics, NextGen® Patient Portal ("NextMD.com"), NextGen® Document Management, NextGen® ePrescribing, NextGen® Mobile, and NextGen® NextPen. The interoperability solutions consist of NextGen® EHR Connect, NextGen® Health Information Exchange ("HIE"), and NextGen® Share. The NextGen Division also offers hosting services, NextGuard data protection services, professional consulting services, such as strategic governance models and operational transformation, technical consulting services, such as data conversions or interface development, and physician consulting services. The NextGen Division products utilize Microsoft Windows technology and can operate in a client-server environment as well as via private intranet, the Internet, or in an ASP environment. The NextGen Division also provides EDI services, which include electronic submission of claims to insurance providers as well as automated patient statements.
On September 9, 2013, we acquired Mirth, a global leader in health information technology that helps customers achieve interoperability. Operating results associated with Mirth products and services are included in the NextGen Division. The acquisition of Mirth enhances our current enterprise interoperability initiatives and broadens our accountable and collaborative care, population

26



health, disease management and clinical data exchange offerings. Mirth offers a wide variety of products and services utilized by both users of Mirth open code technology as well as a large base of domestic and international paying customers. Product offerings available from Mirth include Mirth Connect, Mirth Results, Mirth Match, Mirth Mail, Mirth Appliance, and Mirth Care Enterprise. As a direct result of the Mirth acquisition, we introduced NextGen®ShareInterest income relates primarily to our customer basemarketable securities. Interest expense relates to our revolving credit agreement that was entered into in November 2013. As our first offering that integrates technologies from both NextGen Healthcare and Mirth, NextGen® Share provides the ability to securely and easily share patient charts and other data with other practices using NextGen Internet based software.
On March 11, 2015, we acquired Gennius, a provider of healthcare data analytics. Gennius's operations are managed under the NextGen Division. The acquisition of Gennius is expected to enhance our current enterprise analytics competencies while broadening business intelligence capabilities for addressing new value-based care requirements.
RCM Services Division. The RCM Services Division, with locations in St. Louis, Missouri, North Canton, Ohio, South Jordan, Utah and Hunt Valley, Maryland, provides technology solutions and consulting services to cover the full spectrum of healthcare providers' RCM needs, from patient access through claims denials, with a primary focus on billing and collection services in order to optimize customers' revenue cycle results, improve cash flow, and decrease accounts receivable days. The RCM Services Division combines a high-touch service modelJanuary 2016 and the NextGen® PM software platformrelated amortization of deferred debt issuance costs. Refer to execute its service offerings, which include billingNote 7, “Line of Credit” of our notes to consolidated financial statements included elsewhere in this Report for additional information. Other expense and collections, claims submissions and reconciliation, coding services, electronic remittance and payment posting, accounts receivable management, patient customer service, advance analytics, charge entry and capture, enrollment credentialing, and software setup, hosting and support.
QSI Dental Division. The QSI Dental Division, co-located with our corporate headquarters in Irvine, California, focuses on developing, marketing and supporting software suites sold to dental group organizations located throughout the United States. The QSI Dental Division sells additional licenses to its legacy products as existing customers expand their operations and also sells its practice management and clinical software solutions to new and existing customers primarily as a cloud-based SaaS model, known as QSIDental Web ("QDW"). QDW is marketedincome relates primarily to multi-location dental group practices in whichnet realized gains and losses on our marketable securities.
Interest expense for the QSI Dental Division has historically been a dominant player. When sold under a SaaS model, QDW offers a lower cost of ownership as it is a cloud-based solution that provides users with access to vital data from any web-enabled device. Further, QSI Dental sells its electronic dental charting software in conjunction with NextGen® PMthree and EHR, which is marketed as NextGen® EDR (“Electronic Dental Record”) to federally qualified health centers (“FQHC”) and other safety-net clinics, as further defined below.
The QSI Dental Division participates jointly with the NextGen Division in providing software and services to safety-net clinics like FQHCs and other safety-net health centers, including public health centers, community health centers, free clinics, as well as rural and tribal health centers. FQHCs and other safety-net clinics are community-based organizations that are funded by the federal government, which provide medical and dental services to underprivileged and underserved communities. The Patient Protection and Affordable Care Act, which was signed into law in March 2010, reserved $11 billion over a multi-year period for FQHCs, creating unprecedented opportunities for FQHCs growth and the formation of new FQHCs. When combined and used in tandem, NextGen® EHR, NextGen® EDR, and NextGen® PM are capable of providing an integrated patient record, which is a unique product in this marketplace that is accessible by both physicians and dentists. In May 2013, NextGen® EDR version 4.3 was ONC-ATCB certified by the Certification Commission for Health Information ("CCHIT®") as a complete EHR and demonstrated compliance with all clinical quality measures for eligible providers.
The QSI Dental Division's legacy practice management software suite, known as Clinical Product Suite (“CPS”), uses a UNIX® operating system and can be fully integrated with the customer server-based practice management software offered by each of our Divisions. When integrated and delivered with the NextGen® PM solution, CPS is re-branded as NextGen® EDR and incorporates a wide range of clinical tools including, but not limited to, periodontal charting and digital imaging of X-ray and inter-oral camera images, that are integrated as part of the electronic patient record. The QSI Dental Division also develops, markets, and provides EDI services to dental practices, including electronic submission of claims to insurance providers as well as automated patient statements.

Overview of Our Results
Consolidated revenue increased 0.8%, or $2.7 million, in the nine months ended December 31, 2016 increased $0.6 million and $2.4 million, respectively, compared to the prior year. The increase is primarily related to the interest expense associated with our revolving credit agreement


and the amortization of deferred debt issuance costs. As of December 31, 2016, we had $25.0 million in outstanding loans under the revolving credit agreement.
All other fluctuations in interest and other income and expense are not deemed significant.
Provision for Income Taxes
The following table presents our provision for income taxes for the three and nine months ended December 31, 2016 and 2015 as (in thousands):
 Three Months Ended December 31, Nine Months Ended December 31,
 2016 2015 2016 2015
Provision for income taxes$2,342
 $1,141
 $3,950
 $8,233
Effective tax rate18.3% 13.5% 22.2% 27.3%
The effective rate for the three months ended December 31, 2016 increased compared to the prior year period. The change isperiod primarily due to the resultimpact of a 16.4% increaselower qualifying production activity deductions in software related subscription services revenues, a 14.9% increase in RCM and related services revenues,the current period, certain non-deductible acquisition-related costs, and a 9.1% increase in EDI and data services revenue, partiallydiscrete valuation allowance, offset by a 14.0% decrease in software licensefederal and hardware revenuestate research and a 19.8% decrease in professional services revenue. development credit and other discrete adjustments.
The increase in subscription services revenue reflects growth in subscriptions related to our interoperability and patient portal product offerings. The increase in RCM and related services revenues are the result of new customer additions and organic growth. The growth in EDI and data services revenue has come from new customers and from further penetration of our existing customer base. The decline in software license and hardware revenue reflects the increasingly saturated markets in which our core software products are sold, and the decline in professional services revenue is due to lower implementation and training revenue resulting from the recent decline in system sales and lower consulting services revenue due to reduced demand from customers.

27



Consolidated gross profit as a percentage of revenue increased to 54.4%effective rate for the nine months ended December 31, 20152016 decreased compared to 53.8% in the prior year period primarily due to improved profitability fromfavorable discrete adjustments for federal and state research and development credit, offset by non-deductible acquisition-related costs, lower qualifying production activity deductions in the current period, and other discrete adjustments.
Net Income
The following table presents our net income (in thousands) and net income per share and for the three and nine months ended December 31, 2016 and 2015:
 Three Months Ended December 31, Nine Months Ended December 31,
 2016 2015 2016 2015
Net income$10,486
 $7,302
 $13,826
 $21,979
Net income per share:       
Basic$0.17
 $0.12
 $0.22
 $0.36
Diluted$0.17
 $0.12
 $0.22
 $0.36
As a result of the foregoing changes in revenue and expense, net income for the three and nine months ended December 31, 2016 decreased $3.2 million and $8.2 million, respectively, compared to the prior year period.
Operating Segment Information
Effective July 1, 2016, we revised our reportable operating segments. As part of our ongoing reorganization efforts, we refined the measurement of our segment data to better reflect our current internal organizational structure whereby certain functions that formerly existed within each individual operating segment have changed. Our operating segments now consist of the Software and Related Solutions segment and the RCM and relatedRelated Services segment, which is consistent with the disaggregated financial information used and evaluated by our chief operating decision maker (consisting of our Chief Executive Officer) to assess performance and make decisions about the allocation of resources. Revenue and gross profit are the key measures of segment profitability used by our chief operating decision maker to measure segment operating performance and to make key business decisions. The revenues and gross profit of each segment are derived from distinct product and services within each segment. The Software and Related Solutions segment aggregates the revenues and gross profit of our software-related products and services, including software license and hardware, software-related subscription services, support and maintenance, EDI and data services, and certain professional services, resulting from more effectivesuch as implementation, training, and consulting. The RCM and Related Services segment aggregates the revenues and gross profit of our RCM services and certain related ancillary service offerings.


Operating segment data for the three and nine months ended December 31, 2016 and 2015 is summarized in the table below. Prior period data has been retroactively reclassified to present all segment information on a comparable basis. The change in reportable segments has no impact to consolidated revenues and consolidated cost management.of revenue, nor does it affect our presentation of revenue and cost of revenue on the consolidated statements of comprehensive income.
Consolidated
 Three Months Ended December 31, Nine Months Ended December 31,
 2016 2015 2016 2015
Revenue:       
Software and Related Solutions$106,958
 $93,927
 $312,854
 $291,783
RCM and Related Services20,910
 22,486
 64,385
 65,313
Hospital Solutions(1)

 619
 
 7,469
Consolidated revenue$127,868
 $117,032
 $377,239
 $364,565
        
Gross profit:       
Software and Related Solutions$71,252
 $58,949
 $204,414
 $184,982
RCM and Related Services7,077
 7,769
 21,337
 20,792
Hospital Solutions(1)

 (69) 
 2,569
Unallocated cost of revenue(2)
(4,813) (3,402) (15,676) (10,138)
Consolidated gross profit$73,516
 $63,247
 $210,075
 $198,205

(1) The former Hospital Solutions Division was divested in October 2015 and therefore, does not represent a distinct operating incomesegment. Historical amounts for Hospital Solutions have not been revised.
(2) Consists of amortization of acquired software technology and amortization of capitalized software costs not allocated to the operating segments for the purposes of measuring performance.
Software and Related Solutions
Software and Related Solutions revenue for the three months ended December 31, 2016 increased 29.0%, or $6.7$13.0 million inand gross profit increased $12.3 million compared to the prior year period. Software and Related Solutions revenue for the nine months ended December 31, 2015 as compared to the prior year period. The increase is mostly due to a 1.9%, or $3.72016 increased $21.1 million increase inand gross profit resulting from the increase in total revenues and improvements in profitability noted above and a decrease of 3.9%, or $2.0increased $19.4 million in research and development costs attributed mostly to higher rates of capitalization of software costs related to the development of enhancements to our ambulatory software products during the nine months ended December 31, 2015 as compared to the prior year period.
NextGen DivisionThe increase in revenues for the three months ended December 31, 2016 was driven by an increase in our software related subscription services attributed mostly to the acquisition of HealthFusion in January 2016 and an increase in EDI revenue from the addition of new clients and further penetration of our existing client base, which were partially offset by a decline in professional services revenue, resulting from a recent decline in demand for our core software products and related services.
NextGen Division revenue decreased by 0.6%The increase in revenues for the nine months ended December 31, 2015, as2016 was also driven by an increase in our software related subscription services attributed mostly to the acquisition of HealthFusion in January 2016 and an increase in EDI revenue from the addition of new clients and further penetration of our existing client base, which were partially offset by a decline in software license and hardware and professional services revenue, resulting from a shift in market dynamics toward cloud-based solutions and away from perpetual license arrangements, resulting in lower client demand for our core software products and related support and maintenance, implementation, training, and consulting services.
The increase in gross profit for the three and nine months ended December 31, 2016 is due primarily to the aforementioned increases in revenue, which were offset by an increase in cost of revenue. Cost of revenue increased due to amortization of the software technology intangible asset acquired from HealthFusion, partially offset by lower amortization of previously capitalized software development costs and lower payroll costs associated with delivering support and maintenance and professional services. Gross profit for the three months ended December 31, 2016 was also positively impacted due to a lower level of sales credits and related reserves compared to the prior year period. Divisional software license and hardware revenue decreased by 11.8% and professional services revenue decreased by 22.9%, offset by an increase of 18.5% in software related subscription services revenue, an increase of 8.4% in EDI and data services revenue, and an increase of 1.7% in support and maintenance revenue. As noted above, the increase in subscription services revenue reflects growth in interoperability subscriptions as well as subscriptions related to our NextGen® Patient Portal product offering while the decrease in software license and hardware revenue and professional services revenue reflects the increasingly saturated markets in which our core software products and services are sold.
NextGen Division operating income (excluding Corporate and unallocated amounts) increased by 0.3% in the nine months ended December 31, 2015, as compared to the prior year period. Although overall operating expenses decreased by 11.4%, or $5.4 million, primarily as a result of lower sales commissions associated with a decline in new system sales and a decrease in other personnel related costs resulting from improved operational efficiency, such benefit was mostly offset by a $5.0 million decline in divisional gross profit caused primarily by a decrease in high-margin software license sales.
Our goals for the NextGen DivisionSoftware and Related Solutions include further enhancement of our existing products, including expansion of our software and service offerings that support pay-for-performance initiatives around accountable care organizations, bringing greater ease of use and intuitiveness to our software products, enhancing our managed cloud and hosting services to lower our clients' total cost of ownership, expanding our interoperability and enterprise analytics capabilities, and further development and enhancements of our portfolio of specialty focused templates within our electronic health records software. We intend to remain at the forefront of upcoming new regulatory requirements, including meaningful use requirements for stimulus payments and recent healthcare reform that is driving the transition towards pay-for-performance, value-based reimbursement models. We believe that the expanded requirements for continued eligibility for incentive payments under meaningful use rules will result in an expanded


replacement market for electronic health records software. We also intend to continue selling additional software and services to existing customers,clients, expanding penetration of connectivity and other services to new and existing customers,clients, and capitalizing on growth and cross selling opportunities within RCM and Related Services. Our acquisition of HealthFusion will allow us expand our client base and cloud-based solution capabilities in the RCM Services Division.ambulatory market and meet the needs of practices of increasing size and complexity. Our acquisitions of Mirth and Gennius improve our competitiveness in the markets and provide new customersclients and expanded markets for the NextGen DivisionSoftware and Related Solutions and also support our strategy to focus on accountable care organizations around interoperability, patient engagements, population health and collaborative care management, and enterprise analytics. We believe we are well-positionedwell-positioned within the evolving healthcare market to deliver products and services that address the growing importance of quality collaborative care and shift from fee-for-service to value-based, pay-for-performance care.
The NextGen Division’s growth isWe believe that our operating results are attributed to a strong brand name and reputation within the marketplace for healthcare information technology software and services and investments in sales and marketing activities, including new marketing campaigns, Internet advertising investments, tradeshow attendance and other expanded advertising and marketing expenditures.
RCM and Related Services Division
RCM and Related Services Division revenue increased 16.8%, or $9.8for the three months ended December 31, 2016 decreased $1.6 million compared to the prior period due to lower net new bookings. Gross profit for the three months ended December 31, 2016 decreased $0.7 million due to the decline in revenues, partially offset by a reduction in employee-related costs.
RCM and Related Services revenue for the nine months ended December 31, 2015. The RCM Services Division benefited mostly from2016 decreased $0.9 million compared to the prior year period due to lower net new customer additions duringbookings. Gross profit for the nine months ended December 31, 2015 as well as organic growth achieved through cross selling RCM services to existing NextGen Division customers.
Divisional operating income (excluding Corporate and unallocated amounts)2016 increased 39.1%, or $3.8$0.5 million in the nine months ended December 31, 2015 as compared to the prior year period primarily due to an increase in divisional gross profit,lower employee related costs, partially offset by higher operating expense related mostly to higher sales commissions associated with the growtha decline in revenue noted above.revenue.
The Company believesWe believe that a significant opportunity exists to continue cross selling RCM services to our existing customers.clients. The portion of existing NextGen customersclients who are using the RCM Services Division's services is approximately 10%. Management isWe are actively pursuing efforts to achieve faster growth from expanded efforts to leverage theour existing NextGen Division's sales force towards selling RCM services. We also believe that ongoing increases in the complexity of medical billing and collections processes, including the migration to value-based reimbursement models, will create additional opportunities for our RCM Services Division.

28



QSI Dental Division
QSI Dental Division revenue increased 3.3%, or $0.4 million in the nine months ended December 31, 2015 primarily due to a $0.3 million increase in software license and hardware revenue and a $0.3 million increase in software related subscription services, offset by a $0.3 million decrease in support and maintenance revenue.
Divisional operating income (excluding Corporate and unallocated amounts) increased 13.2%, or $0.5 million, in the nine months ended December 31, 2015 as compared to the prior year period primarily due to the increase in divisional gross profit associated with the increase in higher-margin software license and software related subscription services revenue noted above.
The QSI Dental Division is well-positioned to sell to the FQHCs market and intends to continue leveraging the NextGen Division's sales force to sell its dental electronic medical records software to practices that provide both medical and dental services, such as FQHCs, which are receiving grants as part of the ARRA. Our goal for the QSI Dental Division is to continue to invest in the new cloud-based QDW platform while aggressively marketing QDW to both new and existing customers.
Hospital Solutions Division
On October 22, 2015, we closed an Asset Purchase Agreement with Quadramed Affinity Corporation in which we sold and assigned substantially all assets and liabilities of the Hospital Solutions Division (“Hospital disposition”). We believe that the Hospital disposition will allow us to focus our efforts and resources on our core ambulatory business. The results of operations included within this management's discussion and analysis reflect the operating results of the Hospital Solutions Division through the date of disposition.
Hospital Solutions Division revenue decreased 43.9% in the nine months ended December 31, 2015. Revenue was primarily impacted by a 70.4% decrease in software, hardware and related revenue and a 48.2% decrease in professional services revenue. These decreases are primarily the result of reduced demand for implementation, training, and consulting services due to a decline in new software sales and because software license and hardware sales and software related subscriptions services revenue in the prior year period were favorably impacted by decreases in reserves for sales credits. Additionally, the Hospital disposition partially contributed to the overall decrease in revenue as compared to the prior year period.
Divisional operating loss (excluding Corporate and unallocated amounts) was $0.9 million for the nine months ended December 31, 2015 as compared to a $2.2 million loss for the prior year period. The improvement in operating results is due mostly to a decrease in selling, general and administrative expenses associated mostly to decline in divisional headcount.
A $1.8 million loss (including related incremental direct costs) on the Hospital disposition was recorded in the nine months ended December 31, 2015 and is reflected as a component of selling, general and administrative expense on our consolidated statements of comprehensive income.
Corporate and unallocated amounts (costs not allocated to the operating segments)
Research and development costs decreased by 3.9% to $49.6 million for the nine months ended December 31, 2015 as compared to $51.6 million for the prior year period attributed mostly to higher rates of capitalization of software costs related to the development of enhancements to our ambulatory software products. Capitalized software costs increased to $11.6 million as compared to $9.5 million for the prior year period while gross expenditures, including both amounts expensed and capitalized, remained consistent with the prior year period. The table below provides a summary of the amount of software costs capitalized in proportion to the amount of gross expenditures for the three and nine months December 31, 2015 and 2014:
 Nine Months Ended December 31,
 2015 2014
Gross expenditures$61,188
 $61,137
Capitalized software costs(11,604) (9,535)
Research and development costs, as reported$49,584
 $51,602
 
 
Capitalized software costs as a percentage of gross expenditures19.0% 15.6%
Amortization of capitalized software costs decreased by 27.1% to $7.4 million for the nine months ended December 31, 2015 as compared to $10.2 million for the prior year period. The decrease in amortization of capitalized software costs is due to certain products being fully amortized. Amortization of capitalized software costs are reflected as cost of revenue on our consolidated statements of comprehensive income. Refer to Note 6, “Capitalized Software Costs” of our notes to the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for an estimate of future amortization of capitalized software costs.

29



Other Corporate and overhead costs increased by $3.6 million to $54.6 million for the nine months ended December 31, 2015 as compared to $51.0 million for the prior year period primarily due to higher bad debt expense and acquisition related costs. In addition, higher utilization of online advertising and media placement has resulted in a 2.4% increase in marketing expense to $9.7 million for the nine months ended December 31, 2015 as compared to $9.4 million for the prior year period.

Comparison of the Three Months Ended December 31, 2015 and December 31, 2014
Net Income. Our net income for the three months ended December 31, 2015 was $7.3 million, or $0.12 per share on both a basic and fully diluted basis. In comparison, we had net income of $6.7 million, or $0.11 per share on both a basic and fully diluted basis for the three months ended December 31, 2014. The $0.6 million increase in net income for the three months ended December 31, 2015 as compared to the prior year period was primarily attributed to the following:
a $4.0 million decrease in research and development costs due to higher rates of capitalization of software costs related to the development of enhancements to our ambulatory software products combined with lower gross expenditures, including both amounts expensed and capitalized, related to lower costs as a result of the Hospital disposition and lower third-party consulting costs, and
a $2.1 million decrease in selling, general and administrative costs due primarily to lower shareholder litigation expense, offset by higher acquisition related costs and the loss on Hospital disposition, partially offset by
a $5.8 million decrease in gross profit due mostly to a decrease in high-margin software license sales.
Revenues. Revenue for the three months ended December 31, 2015 decreased 5.2% to $117.0 million from $123.4 million for the three months ended December 31, 2014. NextGen Division revenue decreased 3.7% to $88.7 million compared to $92.1 million in the three months ended December 31, 2014; RCM Services Division revenue increased 4.9% to $23.0 million from $21.9 million; QSI Dental Division revenue increased 5.5% to $4.7 million from $4.5 million; and Hospital Solutions Division revenue decreased 87.6% to $0.6 million from $5.0 million in the three months ended December 31, 2014.
Software, Hardware and Related. Revenue from consolidated software, hardware and related sales for the three months ended December 31, 2015 decreased 16.3% to $27.9 million from $33.3 million in the prior year period.
The following table summarizes software, hardware and related sales on a consolidated and divisional basis for the three months ended December 31, 2015 and 2014 (in thousands):
  Software License and Hardware Software Related Subscription Services Total Software, Hardware and Related
Three Months Ended December 31, 2015      
NextGen Division $15,663
 $11,220
 $26,883
RCM Services Division 3
 
 3
QSI Dental Division 526
 395
 921
Hospital Solutions Division (42) 90
 48
Consolidated $16,150
 $11,705
 $27,855
Three Months Ended December 31, 2014      
NextGen Division $19,210
 $10,645
 $29,855
RCM Services Division 143
 222
 365
QSI Dental Division 435
 284
 719
Hospital Solutions Division 1,640
 713
 2,353
Consolidated $21,428
 $11,864
 $33,292
Software, hardware and related sales for the NextGen Division decreased by $3.0 million in the three months ended December 31, 2015 compared to the prior year period due primarily to a $3.5 million, or 18.5%, decrease in software license and hardware revenue, offset by an increase of $0.6 million, or 5.4%, in software related subscription services revenue resulting from growth in both our interoperability subscriptions and subscriptions related to our NextGen® Patient Portal product offering. The decline in NextGen Division software license and hardware revenue is principally due to increasing levels of market saturation for core electronic health record and practice management solutions. The NextGen Division’s software license and hardware revenue accounted for 58.3% of divisional software, hardware and related revenue during the three months ended December 31, 2015 compared to 64.3% during the prior year period.

30



The RCM Services Division was not a significant contributor to consolidated software, hardware and related revenue for both the three months ended December 31, 2015 and 2014 as a result of the nature of the division's product and service offering.
Total software, hardware and related sales for the QSI Dental Division increased 28.1%, or $0.2 million, in the three months ended December 31, 2015 versus the same period last year primarily due to higher software license sales and increases in software related subscription services, such as QDW, the Division's cloud-based software solution. QDW is sold primarily as a SaaS solution for which revenue is recognized over an extended period of time rather than upfront.
At the Hospital Solutions Division, software, hardware and related revenue decreased 98.0%, or $2.3 million in the three months ended December 31, 2015 versus the same period last year primarily due to the Hospital disposition in October 2015.
We expect to benefit, over time, from growth in the replacement market, driven by an expected consolidation of electronic health records vendors. We also anticipate the creation of new opportunities in connection with the evolution of healthcare from a fee-for-services reimbursement model to a pay-for-performance model around the management of patient populations. Our acquisitions of Gennius and Mirth provided us with new products and services around population health, collaborative care management, interoperability and enterprise analytics to address these market dynamics. While it remains difficult to assess the relative impact or the timing of positive and negative trends affecting the aforementioned market opportunities, we believe we are well positioned to remain a leader in serving the evolving market needs for healthcare information technology.
Support and Maintenance, RCM, EDI and Professional Services. For the three months ended December 31, 2015, our consolidated revenue from RCM and related services and EDI and data services increased by 5.9%, and 8.4%, respectively, compared to the prior year period. Consolidated revenue from support and maintenance decreased by 8.2% compared to the prior year period as a result of increases in sales credits and related reserves and net customer attrition. Professional services revenue decreased by 2.9% compared to the prior year period due to lower demand for related system sales.
The following table summarizes support and maintenance, RCM and related services, EDI and data services and professional services revenue by category on a consolidated and divisional basis for the three months ended December 31, 2015 and 2014 (in thousands):
  Support and Maintenance RCM and Related Services EDI and Data Services Professional Services
Three Months Ended December 31, 2015        
NextGen Division $36,984
 $
 $18,806
 $6,020
RCM Services Division 55
 21,594
 422
 920
QSI Dental Division 2,006
 
 1,395
 404
Hospital Solutions Division 474
 
 20
 77
Consolidated $39,519
 $21,594
 $20,643
 $7,421
Three Months Ended December 31, 2014        
NextGen Division $38,285
 $
 $17,633
 $6,281
RCM Services Division 152
 20,392
 216
 788
QSI Dental Division 2,166
 
 1,178
 417
Hospital Solutions Division 2,442
 
 24
 158
Consolidated $43,045
 $20,392
 $19,051
 $7,644
Support and maintenance revenue at the NextGen Division for the three months ended December 31, 2015 decreased by 3.4% to $37.0 million from $38.3 million as a result of increases in sales credits and related reserves and net customer attrition. NextGen Division EDI and data services revenue grew 6.7% to $18.8 million compared to $17.6 million in the prior year period. The growth in NextGen EDI revenue has come from new customers and from further penetration of the division’s existing customer base. Professional services revenue for the NextGen Division, which consists primarily of implementation and training and consulting services, decreased 4.2% to $6.0 million in the three months ended December 31, 2015 from $6.3 million in the prior year period due to the softening demand for related system sales, as noted above.
For the three months ended December 31, 2015, RCM and related services revenue increased to $21.6 million compared to $20.4 million in the prior year period. The growth in RCM revenue is primarily attributable to organic growth achieved through cross selling RCM services to existing NextGen Division customers as well as the addition of new customers.
QSI Dental Division support and maintenance for the three months ended December 31, 2015 decreased by $0.2 million as compared to the prior year period due primarily to a shift in customer preference to subscription-based software services as opposed to software licenses that require support and maintenance. Professional services revenue remained consistent while EDI and data services revenue at the QSI Dental Division increased to $1.4 million for the three months ended December 31, 2015 from $1.2 million in the prior year period.

31



For the Hospital Solutions Division, support and maintenance revenue decreased by $2.0 million, or 80.6%, and professional services revenue decreased by $0.1 million, or 68.9%, for the three months ended December 31, 2015 as compared to the prior year period primarily due to the Hospital disposition in October 2015.
We intend to continue to promote support and maintenance, RCM and related services, and EDI and data services to both new and existing customers.
Cost of Revenue. Cost of revenue for the three months ended December 31, 2015 decreased to $53.8 million from $54.4 million in the prior year period and the cost of revenue as a percentage of revenue increased to 46.0% from 44.0%. The increase in cost of revenue as a percentage of revenue principally reflects the decline in high-margin software license sales.
The following table details revenue and cost of revenue on a consolidated and divisional basis for the three months ended December 31, 2015 and 2014 (in thousands):
  Three Months Ended December 31,
  2015 % 2014 %
NextGen Division        
Revenue $88,693
 100.0 % $92,054
 100.0%
Cost of revenue 32,497
 36.6 % 30,678
 33.3%
Gross profit $56,196
 63.4 % $61,376
 66.7%
RCM Services Division        
Revenue $22,994
 100.0 % $21,913
 100.0%
Cost of revenue 15,105
 65.7 % 14,757
 67.3%
Gross profit $7,889
 34.3 % $7,156
 32.7%
QSI Dental Division        
Revenue $4,726
 100.0 % $4,480
 100.0%
Cost of revenue 2,093
 44.3 % 2,114
 47.2%
Gross profit $2,633
 55.7 % $2,366
 52.8%
Hospital Solutions Division        
Revenue $619
 100.0 % $4,977
 100.0%
Cost of revenue 688
 111.1 % 2,954
 59.4%
Gross profit (loss) $(69) (11.1)% $2,023
 40.6%
Unallocated cost of revenue $3,402
 N/A
 $3,857
 N/A
Consolidated        
Revenue $117,032
 100.0 % $123,424
 100.0%
Cost of revenue 53,785
 46.0 % 54,360
 44.0%
Gross profit $63,247
 54.0 % $69,064
 56.0%
Gross profit margin for the NextGen Division decreased to 63.4% for the three months ended December 31, 2015 as compared to 66.7% for the prior year period due to a decrease in high-margin software sales. Gross profit margin for the RCM Services Division increased to 34.3% as compared to 32.7% for the prior year period primarily due to improved management of headcount and related costs. The Hospital Solutions Division experienced a gross loss of 11.1% for the three months ended December 31, 2015 primarily due to the Hospital disposition in October 2015.

32



The following table details the individual components of cost of revenue and gross profit (loss) as a percentage of total revenue on a consolidated and divisional basis for the three months ended December 31, 2015 and 2014:
  Software License and Hardware Software Related Subscription Services Support and Maintenance RCM and Related Services EDI and Data Services Professional Services 
Total Cost
of Revenue
 Gross Profit (Loss)
Three Months Ended December 31, 2015                
NextGen Division 3.3% 6.1% 7.1% 0.0% 12.7% 7.4% 36.6% 63.4 %
RCM Services Division 0.0% 0.0% 0.1% 62.5% 1.6% 1.5% 65.7% 34.3 %
QSI Dental Division 3.8% 1.7% 14.2% 0.0% 17.0% 7.6% 44.3% 55.7 %
Hospital Solutions Division 3.5% 12.7% 87.8% 0.0% 1.4% 5.7% 111.1% (11.1)%
Consolidated 5.6% 4.7% 6.4% 12.3% 10.6% 6.4% 46.0% 54.0 %
Three Months Ended December 31, 2014                
NextGen Division 3.5% 5.3% 5.5% 0.0% 11.9% 7.1% 33.3% 66.7 %
RCM Services Division 0.0% 0.0% 0.3% 65.0% 0.8% 1.2% 67.3% 32.7 %
QSI Dental Division 3.9% 1.1% 14.6% 0.0% 18.2% 9.4% 47.2% 52.8 %
Hospital Solutions Division 0.1% 4.7% 32.4% 0.0% 0.4% 21.8% 59.4% 40.6 %
Consolidated 5.9% 4.2% 6.0% 11.5% 9.7% 6.7% 44.0% 56.0 %
Cost of software license and hardware decreased to 5.6% of total revenue during the three months ended December 31, 2015 as compared to 5.9% for the prior year period, which is mainly the result of the full amortization of certain software products, leading to a decrease in related amortization of capitalized software costs. The decline in cost of software license and hardware was offset by an increase in cost of support and maintenance, which increased to 6.4% of total revenue for the three months ended December 31, 2015 as compared to 6.0% for the prior year period, attributable to headcount growth and higher related payroll and benefits expense associated with delivering our products and services at the NextGen Division.
Cost of RCM and related services increased to 12.3% of total revenue and cost of EDI and data services increased to 10.6% of total revenue for the three months ended December 31, 2015 as compared to 11.5% and 9.7%, respectively, for the prior year period. The increase in such costs as a percentage of total revenue is attributed to RCM and related services revenue and EDI and data services revenue each comprising a larger proportion of total revenues in comparison to the prior year period.
Cost of software related subscription services also increased to 4.7% of total revenue for the three months ended December 31, 2015 compared to 4.2% for the prior year period, which is primarily a result of an increase in the absolute level of payroll and benefit expenses associated with delivering our products and services due to headcount additions required to support revenue growth.
We experienced a decline in cost of professional services, which decreased to 6.4% of total revenue during the three months ended December 31, 2015 as compared to 6.7% for the prior year period, due to lower headcount in the Hospital Solutions Division as a result of the disposition and improved cost and utilization management in the NextGen Division.
As a result of the foregoing events and activities, our gross profit percentage decreased to 54.0% for the three months ended December 31, 2015 versus 56.0% for the prior year period.
Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months ended December 31, 2015 decreased 5.0% to $39.4 million as compared to $41.5 million for the prior year period. The decrease in selling, general and administrative expenses consists primarily of:
$4.6 million decrease in legal expense related mostly to lower shareholder litigation defense costs;
$0.8 million decrease in sales commissions expense related to the recent decline in new system sales;
$0.6 million decrease in equipment and depreciation expense;
$0.5 million decrease in consulting and outside services costs; and
$1.1 million net decrease in other selling, general and administrative expenses, offset by
$3.7 million increase in acquisition related costs; and
$1.8 million loss (including related incremental direct costs) on the Hospital disposition.


33



Share-based compensation expense was approximately $0.6 million for both of the three months ended December 31, 2015 and 2014 and is included in the aforementioned amounts. Selling, general and administrative expenses as a percentage of revenue decreased from 33.6% in the three months ended December 31, 2014 to 33.7% in the three months ended December 31, 2015.
Research and Development Costs. Research and development costs for the three months ended December 31, 2015 and 2014 were $14.5 million and $18.5 million, respectively. Research and development costs as a percentage of revenue decreased to 12.4% in the three months ended December 31, 2015 from 15.0% for the prior year period. The decrease in research and development expenses is primarily due to higher rates of capitalization of software costs related to the development of enhancements to our ambulatory software products combined with lower gross expenditures, including both amounts expensed and capitalized, related to lower costs as a result of the Hospital disposition and lower third-party consulting costs.
The capitalization of software development costs results in a reduction to reported research and development costs. For the three months ended December 31, 2015 and 2014, our additions to capitalized software were $4.9 million and $3.2 million, respectively. For the three months ended December 31, 2015 and 2014, total gross research and development expenditures, including both amounts expensed and capitalized, was $19.4 million and $21.7 million, respectively.
We intend to continue to invest heavily in research and development to enhance our software to meet the Meaningful Use definitions under the ARRA and continue to bring additional functionality and features to the medical community.
Amortization of Acquired Intangible Assets. Amortization included in operating expenses related to acquired intangible assets remained consistent at $0.9 million for the three months ended December 31, 2015 compared to the prior year period.
Provision for Income Taxes. The provision for income taxes for the three months ended December 31, 2015 and 2014 was $1.1 million and $1.5 million, respectively. The effective tax rates were 13.5% and 17.9% for the three months ended December 31, 2015 and 2014, respectively. Both periods reflect approximately three quarters of a full fiscal year impact of the federal research and development tax credit due to the timing of the expiration and retroactive reinstatement of the credit. The effective rate for the three months ended December 31, 2015 decreased as compared to the prior year period primarily due to a favorable impact of the qualifying production activity deduction in the three months ended December 31, 2015.

Comparison of the Nine Months Ended December 31, 2015 and December 31, 2014
Net Income. Our net income for the nine months ended December 31, 2015 was $22.0 million, or $0.36 on both a basic and fully diluted basis. In comparison, we earned $16.6 million, or $0.28 and $0.27 per share on a basic and fully diluted basis, respectively, for the nine months ended December 31, 2014. The $5.4 million increase in net income for the nine months ended December 31, 2015 as compared to the prior year period was primarily attributed to the following: Services.

a $3.7 million increase in consolidated gross profit due to improved profitability from software related subscription services, RCM and related services, EDI and data services, and professional services, and
a $2.0 million decrease in research and development expenses due to higher rates of capitalization of software costs related to the development of enhancements to our ambulatory software products, and
a $0.9 million decrease in selling, general and administrative costs due primarily to lower shareholder litigation expense, offset by higher acquisition related costs and the loss on Hospital disposition, partially offset by
an increase of $1.6 million in the provision for income taxes, principally reflecting the increase in pretax income.
Revenue. Revenue for the nine months ended December 31, 2015 increased 0.8% to $364.6 million from $361.8 million for the nine months ended December 31, 2014. NextGen Division revenue decreased 0.6% to $275.3 million from $276.9 million in the nine months ended December 31, 2014, RCM Services Division revenue increased 16.8% to $68.0 million from $58.2 million, QSI Dental Division revenue increased 3.3% to $13.8 million from $13.4 million, and Hospital Solutions Division revenue decreased 43.9% to $7.5 million from $13.3 million in the prior year period.
Software, Hardware and Related. Revenue from consolidated software, hardware and related sales for the nine months ended December 31, 2015 decreased 3.7% to $88.4 million from $91.8 million in the prior year period.

34



The following table summarizes software, hardware and related sales on a consolidated and divisional basis for the nine months ended December 31, 2015 and 2014 (in thousands):
  Software License and Hardware Software Related Subscription Services Total Software, Hardware and Related
Nine Months Ended December 31, 2015      
NextGen Division $49,861
 $33,505
 $83,366
RCM Services Division 234
 743
 977
QSI Dental Division 1,863
 996
 2,859
Hospital Solutions Division 68
 1,144
 1,212
Consolidated $52,026
 $36,388
 $88,414
Nine Months Ended December 31, 2014      
NextGen Division $56,544
 $28,284
 $84,828
RCM Services Division 345
 242
 587
QSI Dental Division 1,590
 677
 2,267
Hospital Solutions Division 2,026
 2,063
 4,089
Consolidated $60,505
 $31,266
 $91,771
NextGen Division software, hardware and related sales decreased by $1.5 million primarily due to a $6.7 million, or 11.8%, decrease in software license and hardware sales during the nine months ended December 31, 2015 versus the same period last year, which is the result of lower sales to both new and existing customers and reflects the increasing levels of market saturation for core electronic health record and practice management solutions. The decrease in software license and hardware sales was partially offset by a $5.2 million, or 18.5%, increase in software related subscription services during the nine months ended December 31, 2015 versus the same period last year as a result of the growth in both our interoperability subscriptions and subscriptions related to our NextGen® Patient Portal product offering. The NextGen Division’s software license and hardware revenue accounted for 59.8% of divisional software, hardware and related revenue during the nine months ended December 31, 2015 compared to 66.7% during the prior year period. 
The RCM Services Division was not a significant contributor to consolidated software, hardware and related revenue for both the nine months ended December 31, 2015 and 2014 as a result of the nature of the division's product and service offering.
Total software, hardware and related sales for the QSI Dental Division increased 26.1%, or $0.6 million, in the nine months ended December 31, 2015 compared to the same period last year, driven mostly by a 47.1% growth in sales of software related subscription services. The growth in software related subscription services versus the same period last year is primarily due to a shift in customer preference from software licenses to software related subscription services, such as QDW, the Division's cloud-based software solution. QDW is sold primarily as a SaaS solution for which revenue is recognized over an extended period of time rather than upfront.
At the Hospital Solutions Division, total software, hardware and related sales decreased 70.4%, or $2.9 million, to $1.2 million in the nine months ended December 31, 2015 as compared to $4.1 million in the prior year period. This decrease is primarily the result of the Hospital disposition in October 2015 as well as higher volume of sales credits for both software license and hardware sales and software related subscriptions services in the nine months ended December 31, 2015 as compared the prior year period.
Support and Maintenance, RCM, EDI and Professional Services. For the nine months ended December 31, 2015, our consolidated revenue from RCM and related services and EDI and data services increased by 14.9%, and 9.1%, respectively compared to the prior year period. Consolidated revenue from support and maintenance decreased by 0.5% compared to the prior year period as a result of net customer attrition. Professional services revenue decreased by 19.8% compared to the prior year period due to lower demand for related system sales.

35



The following table summarizes support and maintenance, RCM and related services, EDI and data services and professional services revenue by category on a consolidated and divisional basis for the nine months ended December 31, 2015 and 2014 (in thousands):
  Support and Maintenance RCM and Related Services EDI and Data Services Professional Services
Nine Months Ended December 31, 2015        
NextGen Division $113,957
 $
 $56,195
 $21,764
RCM Services Division 263
 62,630
 1,262
 2,857
QSI Dental Division 5,925
 
 3,895
 1,146
Hospital Solutions Division 5,263
 
 61
 933
Consolidated $125,408
 $62,630
 $61,413
 $26,700
Nine Months Ended December 31, 2014        
NextGen Division $112,014
 $
 $51,862
 $28,212
RCM Services Division 430
 54,517
 596
 2,095
QSI Dental Division 6,209
 
 3,724
 1,180
Hospital Solutions Division 7,332
 
 94
 1,801
Consolidated $125,985
 $54,517
 $56,276
 $33,288
Support and maintenance revenue at the NextGen Division for the nine months ended December 31, 2015 increased by 1.7% to $114.0 million from $112.0 million for the prior year period primarily due to additional revenues from both new and existing customers as well as declines in sales credits and related reserves. NextGen Division EDI and data services revenue grew 8.4% to $56.2 million compared to $51.9 million in the prior year period. The growth in NextGen EDI revenue has come from new customers and from further penetration of the division’s existing customer base. Professional services revenue for the NextGen Division, which consists primarily of implementation and training and consulting services, decreased 22.9% to $21.8 million in the nine months ended December 31, 2015 from $28.2 million in the prior year period due to the softening demand for related system sales, as noted above.
For the nine months ended December 31, 2015, RCM and related services revenue increased to $62.6 million compared to $54.5 million in the prior year period. The growth in RCM revenue is primarily attributable to organic growth achieved through cross selling RCM services to existing NextGen Division customers as well as the addition of new customers.
QSI Dental Division support and maintenance revenue for the nine months ended December 31, 2015 decreased by $0.3 million as compared to the prior year period due primarily to a shift in customer preference to subscription-based software services as opposed to software licenses that require support and maintenance. EDI and data services revenue and professional services revenue at the QSI Dental Division remained consistent for the nine months ended December 31, 2015 compared to the prior year period.
For the Hospital Solutions Division, support and maintenance revenue for the nine months ended December 31, 2015 decreased by $2.1 million, or 28.2%, as compared to the prior year period. Professional services revenue decreased by $0.9 million, or 48.2%, as compared to the prior year period due to lower demand for system sales and related implementation, training, and consulting services. The Hospital disposition in October 2015 also partially contributed to the overall decrease in revenue as compared to the prior year period.
Cost of Revenue. Cost of revenue for the nine months ended December 31, 2015 decreased by 0.6% to $166.4 million from $167.3 million in the prior year period and the cost of revenue as a percentage of revenue decreased to 45.6% from 46.2%. The decrease in cost of revenue as a percentage of revenue reflects a $2.8 million decrease in amortization of capitalized software costs as compared to the prior year period due to certain software products becoming fully amortized.

36



The following table details revenue and cost of revenue on a consolidated and divisional basis for the nine months ended December 31, 2015 and 2014 (in thousands):
  Nine Months Ended December 31,
  2015 % 2014 %
NextGen Division        
Revenue $275,282
 100.0% $276,914
 100.0%
Cost of revenue 98,866
 35.9% 95,459
 34.5%
Gross profit $176,416
 64.1% $181,455
 65.5%
RCM Services Division        
Revenue $67,989
 100.0% $58,226
 100.0%
Cost of revenue 45,630
 67.1% 41,633
 71.5%
Gross profit $22,359
 32.9% $16,593
 28.5%
QSI Dental Division        
Revenue $13,825
 100.0% $13,379
 100.0%
Cost of revenue 6,825
 49.4% 6,818
 51.0%
Gross profit $7,000
 50.6% $6,561
 49.0%
Hospital Solutions Division        
Revenue $7,469
 100.0% $13,318
 100.0%
Cost of revenue 4,901
 65.6% 10,723
 80.5%
Gross profit $2,568
 34.4% $2,595
 19.5%
Unallocated cost of revenue $10,138
 N/A
 $12,690
 N/A
Consolidated        
Revenue $364,565
 100.0% $361,837
 100.0%
Cost of revenue 166,360
 45.6% 167,323
 46.2%
Gross profit $198,205
 54.4% $194,514
 53.8%
Gross profit margin for the NextGen Division decreased to 64.1% for the nine months ended December 31, 2015 compared to 65.5% for the prior year period primarily due to a decrease in high-margin software license sales. Gross profit margin for the RCM Services Division increased to 32.9% as compared to 28.5% for the prior year period primarily due to improved management of headcount and related costs. The gross profit margin for the Hospital Solutions Division of 34.4% for the nine months ended December 31, 2015 benefited from a significant decline in cost of revenue due mostly to lower payroll and related benefits costs, in connection with reductions in headcount and the Hospital disposition in October 2015.
The following table details the individual components of cost of revenue and gross profit as a percentage of total revenue on a consolidated and divisional basis for the nine months ended December 31, 2015 and 2014:
  Software License and Hardware Software Related Subscription Services Support and Maintenance RCM and Related Services EDI and Data Services Professional Services Total Cost
of Revenue
 Gross Profit
Nine Months Ended December 31, 2015                
NextGen Division 3.4% 6.0% 6.6% 0.0% 12.3% 7.6% 35.9% 64.1%
RCM Services Division 0.0% 0.0% 0.1% 64.1% 1.5% 1.4% 67.1% 32.9%
QSI Dental Division 4.1% 1.9% 14.5% 0.0% 17.8% 11.1% 49.4% 50.6%
Hospital Solutions Division��2.7% 8.3% 48.8% 0.0% 0.3% 5.5% 65.6% 34.4%
Consolidated 5.5% 4.8% 6.5% 12.0% 10.2% 6.6% 45.6% 54.4%
Nine Months Ended December 31, 2014                
NextGen Division 3.2% 5.0% 5.0% 0.0% 11.9% 9.4% 34.5% 65.5%
RCM Services Division 0.0% 0.0% 0.2% 69.0% 0.9% 1.4% 71.5% 28.5%
QSI Dental Division 4.9% 2.2% 14.9% 0.0% 17.8% 11.2% 51.0% 49.0%
Hospital Solutions Division 0.2% 6.8% 38.9% 0.0% 0.4% 34.2% 80.5% 19.5%
Consolidated 6.2% 4.2% 5.8% 11.1% 9.9% 9.0% 46.2% 53.8%
During the nine months ended December 31, 2015, cost of software license and hardware decreased to 5.5% of revenue compared to 6.2% for the prior year period, which is mainly the result of the full amortization of certain software products, leading to a decrease in related amortization of capitalized software costs. The decline in cost of software license and hardware was offset by a increases in cost of software related subscription services and support and maintenance, which increased to

37



4.8% and 6.5%, respectively, for the nine months ended December 31, 2015 as compared to 4.2% and 5.8%, respectively, for the prior year period, attributable to headcount growth and higher related payroll and benefits expense associated with delivering our products and services at the NextGen Division.
Cost of RCM and related services increased to 12.0% of total revenue and cost of EDI and data services increased to 10.2% of total revenue for the nine months ended December 31, 2015 as compared to 11.1% and 9.9%, respectively, for the prior year period. The increase in such costs as a percentage of total revenue is attributed to RCM and related services revenue and EDI and data services revenue each comprising a larger proportion of total revenues in comparison to the prior year period.
For the Hospital Solutions Division, gross profit as a percentage of total revenue increased significantly to 34.4% for the nine months ended December 31, 2015 from 19.5% for the prior year period primarily attributed to a significant decline in cost of professional services, which decreased to 5.5% of revenue during the nine months ended December 31, 2015 compared to 34.2% for the prior year period, due to lower headcount and improved cost and utilization management. The NextGen Division also experienced a decline in cost of professional services to 7.6% of revenue during the nine months ended December 31, 2015 compared to 9.4% for the prior year period also due to lower headcount and improved cost and utilization management. The absolute level of professional services costs decreased by $8.8 million, of which $4.8 million of the decrease is related to the NextGen Division and $4.1 million relates to the Hospital Solutions Division.
As a result of the foregoing events and activities, our gross profit percentage increased to 54.4% for the nine months ended December 31, 2015 versus 53.8% for the same prior year period.
Selling, General and Administrative Expenses. Selling, general and administrative expenses for the nine months ended December 31, 2015 decreased 0.8% to $116.0 million as compared to $116.9 million for the prior year period. The decrease in selling, general and administrative expenses consists primarily of:
$3.1 million decrease in legal expense related mostly lower shareholder litigation defense costs;
$1.6 million decrease in sales commission expense related to the recent decline in new system sales;
$1.3 million decrease in consulting and outside services costs;
$0.9 million decrease in equipment and depreciation expense;
$0.8 million decrease in facilities costs as the prior year period included certain lease termination fees; and
$0.3 million net decrease in other selling and administrative expenses, offset by
$3.2 million increase in acquisition related costs;
$2.1 million increase in bad debt expense because the prior year period included a net bad debt benefit (i.e., a credit) to earnings, related to aggressive working capital management in that period; and
$1.8 million loss (including related incremental direct costs) on the Hospital disposition.
Share-based compensation expense was approximately $1.7 million and $2.1 million for the nine months ended December 31, 2015 and 2014, respectively, and is included in the aforementioned amounts. Selling, general and administrative expenses as a percentage of revenue decreased from 32.3% in the nine months ended December 31, 2014 to 31.8% in the nine months ended December 31, 2015.
Research and Development Costs. Research and development costs for the nine months ended December 31, 2015 and 2014 were $49.6 million and $51.6 million, respectively. Research and development costs as a percentage of revenue decreased to 13.6% in the nine months ended December 31, 2015 from 14.3% for the prior year period. The decrease in research and development expenses is primarily due to higher rates of capitalization of software costs related to the development of enhancements to our ambulatory software products.
The capitalization of software development costs results in a reduction to reported research and development costs. For the nine months ended December 31, 2015 and 2014, our additions to capitalized software were $11.6 million and $9.5 million, respectively. For the nine months ended December 31, 2015 and 2014, total gross research and development expenditures including both amounts expensed and capitalized was $61.2 million and $61.1 million, respectively.
Amortization of Acquired Intangible Assets. Amortization included in operating expenses related to acquired intangible assets decreased to $2.7 million for the nine months ended December 31, 2015 from $2.8 million in the prior year period.
Provision for Income Taxes. The provision for income taxes for the nine months ended December 31, 2015 and 2014 was $8.2 million and $6.7 million, respectively. The effective tax rate was 27.3% and 28.6% for the nine months ended December 31, 2015 and 2014, respectively. The effective rate for the nine months ended December 31, 2015 decreased as compared to the prior year period primarily due to a favorable impact of the qualifying production activity deduction in the nine months ended December 31, 2015.

38



Liquidity and Capital Resources
The following table presents selected financial statistics and information for the nine months ended December 31, 20152016 and 20142015 (in thousands):
Nine Months Ended December 31,Nine Months Ended December 31,
2015 20142016 2015
Cash and cash equivalents and marketable securities$104,813
 $124,822
$23,994
 $104,813
Net increase (decrease) in cash and cash equivalents and marketable securities$(25,772) $11,021
Unused portion of revolving credit agreement(1)225,000
 
Total liquidity$248,994
 $104,813
   
Net income$21,979
 $16,589
$13,826
 $21,979
Net cash provided by operating activities$27,292
 $58,706
$81,423
 $27,292
Number of days of sales outstanding (1)72
 78
_________________________
(1) Days sales outstanding is equal to accounts receivable divided by average daily revenue.
Cash Flows from Operating Activities
The following table summarizes our consolidated statements As of cash flows for the nine months ended December 31, 2015 and 2014 (in thousands):2016, we had our outstanding loans of $25.0 million under our $250.0 million revolving credit agreement.
  Nine Months Ended December 31,
  2015 2014
Net income $21,979
 $16,589
Non-cash expenses 27,426
 26,577
Cash from net income (as adjusted) 49,405
 43,166
Change in accounts receivable 11,313
 8,779
Change in other assets and liabilities (33,426) 6,761
Net cash provided by operating activities $27,292
 $58,706
For the nine months ended December 31, 2015,Our principal sources of liquidity are our cash provided by operating activities declined by $31.4 million to $27.3 milliongenerated from $58.7 millionfor the prior year period, which was caused by a $40.2 million decline attributed to changes in other assets and liabilities, partially offset by an increase of $5.4 million in cash flows due to higher net income in the current year. The reduction in cash flows due to changes in other assets and liabilities for the nine months ended December 31, 2015 isoperations, driven mostly attributed to payments of accrued bonuses related to the fiscal 2015 incentive compensation plans, payments of income taxes during the period, a decline in professional services deferred revenue due to the softening demand for related system sales, as previously noted, and a decline in support and maintenance deferred revenue due to the timing of invoicing as compared to the rendering of such services. Although net cash provided by operating activities for the nine months ended December 31, 2015 declined as compared to the prior year period, cash provided by operating activities has historically been, and is expected to continue to be, our primary source of cash, driven by our net income and working capital management.
A key component of working capital management, involves the collection of accounts receivable. Changes in accounts receivable provided $11.3 million and $8.8 million in net cash from operating activities for the nine months ended December 31, 2015 and 2014, respectively. Further, the effectiveness of working capital management can be measured by days sales outstanding (“DSO”) of accounts receivable. DSO decreased to 72 days during the nine months ended December 31, 2015, as compared to 78 days during the prior year period, reflecting continued improvement of our accounts receivable management.
Cash Flows from Investing Activities
Net cash used in investing activities for the nine months ended December 31, 2015 and 2014 was approximately $22.2 million and $15.6 million, respectively. The $6.6 million increase in net cash used in investing activities is primarily due to a $2.1 million increase in additions to capitalized software costs, $4.5 million increase in cash used for additions to equipment and improvements, and $5.0 million decrease in proceeds from sales and maturities of marketable securities, offset by a $5.0 million decrease in purchases of marketable securities.
Cash Flows from Financing Activities
Net cash used in financing activities for the nine months ended December 31, 2015 and 2014 was $31.4 million and $32.6 million, respectively. During the nine months ended December 31, 2015, we paid $32.1 million in dividends to shareholders, the impact of which was offset by proceeds of $0.7 million from the issuance of shares under employee plans. In comparison, during the prior

39



year period, we also paid $32.1 million in dividends to shareholders and $0.7 million in contingent consideration related to prior acquisitions.
Cash and Cash Equivalents and Marketable Securities
At December 31, 2015, our combined cash and cash equivalents, and marketable securitiesthe Credit Agreement.
Cash and Cash Equivalents
As of December 31, 2016, our cash and cash equivalents balance of $104.8$24.0 million reflects a $12.5 million decrease compared to $36.5 million of $25.8 million from the comparable balancecash, cash equivalents and marketable securities as of March 31, 2015.2016. This decrease principally reflects: a) significant cash payments made in the current fiscal year related to fiscal 2015 accruals for incentive compensation plans and income taxes owing from such year; b) increasesprimarily reflects $80.0 million of principal repayments on our revolving line of credit, partially offset by an increase in cash used for investing activities, including additions to capitalized software costs and equipment and improvements; and c) the distribution of significant dividend payments, the aggregate amount of which exceeded our cash flow provided by operating activities.activities as discussed further below, and payment of dividends in the prior year period.
In January 2016, we entered into a $250.0 million revolving credit agreement (the "Credit Agreement") with JPMorgan Chase Bank, N.A., as administrative agent, U.S. Bank National Association, as syndication agent, and certain other lenders. Our outstanding loans under the Credit Agreement was $25.0 million as of December 31, 2016.


We may continue to use a portion of our funds as well as available financing from the Credit Agreement for future acquisitions or other similar business activities, although the specific timing and amount of funds to be used is not currently determinable. Our principal sources of liquidity are our cash and cash equivalents, the Credit Agreement, as well as our cash generated from operations. We intend to expend some of our available funds for the development of products complementary to our existing product line as well as new versions of certain of our products. These developments are intended to take advantage of more powerful technologies and to increase the integration of our products. Such expenditures will be funded from cash on hand and cash flows from operations.
Our investment policy is determined by our Board of Directors. We currently maintain ourExcess cash, if any, may be invested in very liquid short term assets including tax exempt and taxable money market funds, certificates of deposit and short term municipal bonds with average maturities of 365 days or less at the time of purchase. Our Board of Directors continues to review alternate uses for our cash including an expansion of our investment policy and other items. Any or all of these programs could significantly impact our investment income in future periods.
On January 4, 2016, we entered into a $250.0 million revolving credit agreement (the "Credit Agreement") with JPMorgan Chase Bank, N.A., as administrative agent, U.S. Bank National Association, as syndication agent, and certain other lenders. The initial draw down on the Credit Agreement was approximately $173.5 million. Also on January 4, 2016, we completed our acquisition of HealthFusion Holdings, Inc. ("HealthFusion") pursuant to the Agreement and Plan of Merger dated October 30, 2015, which is part of our strategy to expand the HealthFusion client base and cloud-based solution capabilities in the ambulatory market. This acquisition was funded by our initial draw down of the Credit Agreement, a portion of which has been subsequently repaid fromWe believe that our cash on hand. We may continue to use a portion of our funds in connection with future acquisitions or other similar business activities, although the specific timing and amount of funds to be used is not currently determinable.
Our future practice concerning the payment of dividends is uncertain. The Credit Agreement contains restrictions on our ability to declare and pay dividends subsequent to the previously declared January 4, 2016 dividend payment, and management does not expect to pay additional dividends for at least the next twelve months. Payment of future dividends, if any, will be at the discretion of our Board of Directors after taking into account various factors, including without limitation, the Credit Agreement, operating cash flows, financial condition, operating results, and sufficiency of funds based on our current and anticipated cash needs and capital requirements.
Management believes that its cash, cash equivalents and marketable securities on hand at December 31, 2015,2016, together with itsour cash flows from operations and liquidity provided by the Credit Agreement, will be sufficient to meet itsour working capital and capital expenditure requirements for the next twelve months.

Cash Flows from Operating Activities
The following table summarizes our consolidated statements of cash flows for the nine months ended December 31, 2016 and 2015 (in thousands):
 Nine Months Ended December 31,
 2016 2015
Net income$13,826
 $21,979
Non-cash expenses45,613
 27,426
Cash from net income, as adjusted$59,439
 $49,405
    
Change in deferred revenue$(8,195) $(10,320)
Change in accounts receivable16,005
 11,313
Change in other assets and liabilities14,174
 (23,106)
Net cash provided by operating activities$81,423
 $27,292
For the nine months ended December 31, 2016, cash provided by operating activities increased $54.1 million compared to the prior year period. The increase is primarily due to a $36.5 million increase in cash flows from changes in income taxes, $10.0 million higher net income, as adjusted for non-cash expenses, and a $6.8 million increase from changes in accounts receivable and deferred revenue. Non-cash expenses increased to $45.6 million for the nine months ended December 31, 2016 compared to $27.4 million in the prior year primarily due to higher amortization of intangibles associated with the acquisition of HealthFusion and changes in the fair value of contingent consideration liabilities.
Cash Flows from Investing Activities
Net cash used in investing activities for the nine months ended December 31, 2016 was $5.6 million compared with $22.2 million in the prior year period. The $16.6 million decrease in net cash used in investing activities is primarily due to $9.3 million of cash proceeds from the sales of marketable securities in the nine months ended December 31, 2016 compared to $0.7 million of net purchases in the prior year period, a $5.2 million decrease in additions to capitalized software, and a $1.7 million decrease in additions to equipment and improvements.
Cash Flows from Financing Activities
Net cash used in financing activities for the nine months ended December 31, 2016 was $79.0 million compared with $31.4 million in the prior year period. The increase in cash used in financing activities relates to $80.0 million of principal repayments on our revolving line of credit in the current year period, partially offset by $32.1 million in dividends paid to shareholders during the prior year period.



Contractual Obligations
The following table summarizes our significant contractual obligations at December 31, 20152016 and the effect that such obligations are expected to have on our liquidity and cash in future periods (in thousands):
 For the year ended March 31, For the year ended March 31,
Contractual ObligationsTotal2016 (remaining three months)20172018201920202021 and beyondTotal2017 (remaining three months)20182019202020212022 and beyond
Operating lease obligations(1)$59,968
$1,687
$7,954
$8,529
$7,516
$6,540
$27,742
$71,136
$2,816
$10,980
$10,116
$9,222
$9,226
$28,776
Contingent consideration and other acquisition related liabilities (excluding share-based payments)$900
200
$700
$



Line of credit obligations25,000




25,000

Contingent consideration and other acquisition related liabilities18,567
18,567





Total$60,868
$1,887
$8,654
$8,529
$7,516
$6,540
$27,742
$114,703
$21,383
$10,980
$10,116
$9,222
$34,226
$28,776
_________________________
(1)Operating lease obligations have not been reduced by minimum sublease rentals of $1.9 million due in future periods under our non-cancelable subleases.
The deferred compensation liability as of December 31, 20152016 was $6.7 million, which is not included in the table above as the timing of future benefit payments to employees is not determinable.
The uncertain tax position liability as of December 31, 20152016 was $3.8$4.7 million, which is not included in the table above as the timing of expected payments is not determinable.
Subsequent to December 31, 2015, we entered into the Credit Agreement, which matures on January 4, 2021 and the full balance of the revolving loans and all other obligations under the agreement must be paid at that time. Contractual obligations related to the Credit Agreement are not reflected in the table above.

40



RecentNew Accounting Pronouncements
Refer to Note 1, “Summary of Significant Accounting Policies,”Policies” of our notes to consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for a discussion of new accounting standards.

41




ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

There is littleAs of December 31, 2016, we were subject to nominimal market risk on our cash and cash equivalents as we currently maintainmaintained our cashbalances in very liquid short term assets including tax exempt and taxable money market funds certificates of deposits and short term municipal bonds with average maturities of 36590 days or less at the time of purchase.
AlthoughAs of December 31, 2016, we havehad $25.0 million in outstanding loans under our revolving credit agreement. The revolving loans under the agreement bear interest at our option of either, (a) a base rate based on the highest of (i) the rate of interest per annum publicly announced from time to time by JPMorgan Chase Bank, N.A., as its prime rate, (ii) the greater of (A) the federal funds effective rate and (B) the overnight bank funding rate (as determined by the Federal Reserve Bank of New York) plus 0.50% and (iii) the one-month British Bankers Association London Interbank Offered Rate ("LIBOR") plus 1.00%) plus an applicable margin based on our leverage ratio from time to time, ranging from 0.50% to 1.50%, or (b) a LIBOR-based rate (subject to a floor of 0.00%) plus an applicable margin based on our leverage ratio from time to time, ranging from 1.50% to 2.50%. Accordingly, we are exposed to interest rate risk, primarily changes in LIBOR, due to our loans under the revolving credit agreement. A one hundred basis point (1.00%) change in the interest rate on our outstanding loans as of December 31, 2016 would result in a corresponding change in our annual interest expense of approximately $0.3 million. Refer to Note 7, “Line of Credit” of our notes to consolidated financial statements included elsewhere in this Report for additional information.
As of December 31, 2016, we had international operations that exposed us to the risk of fluctuations in foreign currency exchange rates against the U.S. dollar. However, the impact of foreign currency fluctuations has not been material to our financial position or operating results.

ITEM 4. CONTROLS AND PROCEDURES.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of the Chief Executive Officer and Interim Chief Financial Officer (our principal executive officer and principal financial officer, respectively) have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Security Exchange Act of 1934, as amended, the "Exchange Act") as of December 31, 2015,2016, the end of the period covered by this Quarterly Report on Form 10-Q (the “Evaluation Date”). They have concluded that, as of the Evaluation Date, these disclosure controls and procedures were effective to ensure that material information relating to the Company and its consolidated subsidiaries would be made known to them by others within those entities and would be disclosed on a timely basis. The Chief Executive Officer and Interim Chief Financial Officer have concluded that our disclosure controls and procedures are designed, and are effective, to give reasonable assurance that the information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the rules and forms of the SEC.Securities and Exchange Commission. They have also concluded that the our disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports that are filed or submitted under the Exchange Act are accumulated and communicated to our management, including the Chief Executive Officer and Interim Chief Financial Officer, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
During the quarter ended December 31, 2015,2016, there were no changes in our “internal control over financial reporting” (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

42




PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.
Hussein Litigation
On October 7, 2013, a complaint was filed against our Company and certain of our officers and directors in the Superior Court of the State of California for the County of Orange, captioned Ahmed D. Hussein v. Sheldon Razin, Steven Plochocki, Quality Systems, Inc. and Does 1-10, inclusive, No. 30-2013-00679600-CU-NP-CJC, by Ahmed Hussein, a former director and significant shareholder of our Company. We filed a demurrer to the complaint, which the courtCourt granted on April 10, 2014. An amended complaint was filed on April 25, 2014. The amended complaint generally alleges fraud and deceit, constructive fraud, negligent misrepresentation and breach of fiduciary duty in connection with statements made to our shareholders regarding our financial condition and projected future performance. The amended complaint seeks actual damages, exemplary and punitive damages and costs. We filed a demurrer to the amended complaint. On July 29, 2014, the courtCourt sustained the demurrer with respect to the breach of fiduciary duty claim, and overruled the demurrer with respect to the fraud and deceit claims. On August 28, 2014, we filed an answer and also filed a cross-complaint against the plaintiff, alleging that the plaintiff breached fiduciary duties owed to the Company, Mr. Razin and Mr. Plochocki. Mr. Razin and Mr. Plochocki have dismissed their claims against Hussein, leaving QSI as the sole plaintiff in the cross-complaint. On June 26, 2015, we filed a motion for summary judgment, which the courtCourt granted on September 16, 2015, dismissing all claims against us. On September 23, 2015, the plaintiff filed an application for reconsideration of the Court’s summary judgment order, which the courtCourt denied. On October 28, 2015, the plaintiff filed a motion for summary judgment, seeking to dismiss our cross-complaint. The hearingcross-complaint, which the Court denied on March 3, 2016. On May 9, 2016, the plaintiff'splaintiff filed a motion for summary adjudication, seeking to again dismiss our cross-complaint, which the Court denied on August 5, 2016. On August 5, 2016, the plaintiff filed a motion for judgment on the pleadings, seeking to again dismiss our cross-complaint, which the Court denied on September 2, 2016. Trial is set for February 18, 2016.April 10, 2017 on QSI’s cross-complaint. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.
Federal Securities Class Action
On November 19, 2013, a putative class action complaint was filed on behalf of the shareholders of our Company other than the defendants against us and certain of our officers and directors in the United States District Court for the Central District of California by one of our shareholders. After the courtCourt appointed lead plaintiffs and lead counsel for this action, and recaptioned the action In re Quality Systems, Inc. Securities Litigation, No. 8L13-cv-01818-CJC(JPRx), lead plaintiffs filed an amended complaint on April 7, 2014. The amended complaint, which is substantially similar to the litigation described above under the caption “Hussein Litigation,” generally alleges that statements made to our shareholders regarding our financial condition and projected future performance were false and misleading in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the individual defendants are liable for such statements because they are controlling persons under Section 20(a) of the Exchange Act. The complaint seeks compensatory damages, court costs and attorneys' fees. We filed a motion to dismiss the amended complaint on June 20, 2014, which the courtCourt granted on October 20, 2014, dismissing the complaint with prejudice. Plaintiffs filed a motion for reconsideration of the Court's order, which the courtCourt denied on January 5, 2015. On January 30, 2015, Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Ninth Circuit, captioned In re Quality Systems, Inc. Securities Litigation, No. 15-55173. Plaintiffs filed their opening brief and we answered. Oral argument is not yet scheduled.was held on December 5, 2016. The Court's decision remains pending. We believe that the plaintiffs’ claims are without merit and continue to defend against them vigorously. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.
Shareholder Derivative Litigation
On January 24, 2014, a complaint was filed against our Company and certain of our officers and current and former directors in the United States District Court for the Central District of California, captioned Timothy J. Foss, derivatively on behalf of himself and all others similarly situated, vs. Craig A. Barbarosh, George H. Bristol, James C. Malone, Peter M. Neupert, Morris Panner, D. Russell Pflueger, Steven T. Plochocki, Sheldon Razin, Lance E. Rosenzweig and Quality Systems, Inc., No. SACV14-00110-DOC-JPPx, by Timothy J. Foss, a shareholder of ours. The complaint arises from the same allegations described above under the captions “Hussein Litigation” and “Federal Securities Class Action” and generally alleges breach of fiduciary duties, abuse of control and gross mismanagement by our directors, in addition to unjust enrichment and insider selling by individual directors. The complaint seeks compensatory damages, restitution and disgorgement of all profits, court costs, attorneys’ fees and implementation of enhanced corporate governance procedures. The parties have agreed to stay this litigation until the United States Court of Appeals for the Ninth Circuit issues a ruling on the pending appeal described above under the caption “Federal Securities Class Action”. We believe that the plaintiff’s claims are without merit and intend to defend against them vigorously. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.
In addition to the above, we have experienced legal claims by customers regarding product and contract disputes and from time to time, claims by other third parties asserting that we have infringed their intellectual property rights. We believe that these claims, including those filed by Mr. Hussein, the Deerfield Beach Police Pension Fund and the shareholder derivative action, are without merit and intend to defend against them vigorously; however, we could incur substantial costs and diversion of management resources even if we are ultimately successful in the defense of such claims. Litigation is inherently uncertain and always difficult to predict. We refer you to the discussion of infringement and litigation risks in our “Item 1A. Risk Factors” section of our Annual Report.


43



ITEM 1A. RISK FACTORS.

Our business is subject to many risks and uncertainties, which may materially and adversely affect our future business, prospects, financial condition and results of operations. These risk factors are disclosed in “Item 1A. Risk Factors” in our Annual Report and the risk factors set forth below, which supplement the risk factors previously disclosed.Report.
We are outsourcing our internal audit function, which involves a number of risks that may adversely affect our business and results of operations. We are currently transitioning our internal audit function to a third-party provider. Although we believe that outsourcing this function will ultimately result in lower costs and increased efficiencies, this may not be the case immediately or ever. The transition process to an outsourced internal audit function is complex and time-consuming, which may result in a diversion of management’s time and attention away from business operations. This diversion could have an adverse effect on our business, results of operations and financial condition. In addition, outsourcing our internal audit function means we will be relying upon a third party to meet our needs. Because this third party may not be as responsive to our needs as we would be ourselves, we may increase the risk of disruption to our operations. If our third-party provider terminates its agreement with us and we are unable to replace it with another service provider, our operations may be interrupted. Even a temporary disruption in services could result in significant risk of noncompliance with our duties as a public company, which could have an adverse effect on our business. Moreover, there can be no assurance that a replacement service provider will provide its services at the same or a lower cost than the service provider it replaces. Our business and results of operations may be adversely affected if we experience operating problems and/or cost overruns during the outsourcing transition process or if our outsourced internal audit function does not function as expected or give rise to the expected benefits.
Our new credit agreement contains restrictive and financial covenants that may limit our operational flexibility. If we fail to meet our obligations under the credit agreement, our operations may be interrupted and our business and financial results could be adversely affected. In order to fund our acquisition of HealthFusion, on January 4, 2016, we entered into a revolving credit agreement with various lenders, secured by substantially all of our and our material domestic subsidiaries’ existing and future property. The credit agreement includes certain customary covenants that impose restrictions on our business and financing activities that could limit our operations or flexibility to take certain actions. The credit agreement also contains certain customary affirmative covenants requiring us to maintain specified levels of financial performance. Our ability to comply with these covenants may be affected by events that could be beyond our control. A breach of these covenants could result in an event of default under the credit agreement which, if not cured or waived, could result in the indebtedness becoming immediately due and payable, which in turn could result in material adverse consequences that negatively impact our business, the market price for our common stock, and our ability to obtain financing in the future.
We may not be successful in integrating and operating our HealthFusion acquisition, and in implementing our post-acquisition business strategy. Potential shifts in product focus that may occur as a result of the acquisition may lead to an impairment of previously capitalized development work. We acquired HealthFusion on January 4, 2016. As a result of the acquisition, we will need to devote significant management attention and resources to integrating HealthFusion’s business and product platform into our business, and we may experience problems associated with the acquired company and its personnel, processes, product, technology, and other matters. There is no assurance that we will be able to successfully integrate the HealthFusion business or realize synergies and benefits from the transaction. Furthermore, the acquisition is anticipated to substantially alter our business strategy, increasing our focus on efforts to expand our client base and cloud-based solution capabilities in the ambulatory market. We continue to evaluate the impact of HealthFusion’s existing cloud-based product on our ongoing efforts to develop and release our NextGen Now cloud-based platform. Our assessment may lead us to determine that the HealthFusion product, which is already a production-ready and sellable solution, may represent a more prudent investment in our technical future than continuing with the NextGen Now development plans. If we decide to abandon further development of the previously capitalized NextGen Now platform or certain components thereof, a material impairment of the asset may result. If we are unable to successfully integrate HealthFusion and implement post-acquisition revisions to our business strategy and product focus, our business, financial condition, and results of operations may suffer.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.

ITEM 4. MINE SAFETY DISCLOSURES.
Not Applicable

ITEM 5. OTHER INFORMATION.
None.

44




ITEM 6. EXHIBITS.
Exhibit NumberExhibit DescriptionFiled Herewith
   
10.110.1*CreditForm of Change of Control Severance Agreement, dated asentered into with the Company's named executive officers effective December 27, 2016.
10.2*Form of January 4, 2016, among Quality Systems, Inc., JPMorgan Chase Bank, N.A., as administrative agent, U.S. Bank National Association, as syndication agent,Performance Stock Award Grant Notice and BankPerformance/Restricted Stock Award Agreement for 2015 Equity Incentive Plan, entered into with the Company's named executive officers effective December 29, 2016.
10.3*Form of Restricted Stock Award Grant Notice and Performance/Restricted Stock Award Agreement for 2015 Equity Incentive Plan, entered into with the West, KeyBank National Association and Wells Fargo Bank, National Association, as co-documentation agentsCompany's named executive officers effective December 29, 2016.X
31.1Certification of Principal Executive Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
31.2Certification of Principal Financial Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
32.1Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.X
101.INS**XBRL Instance 
101.SCH**XBRL Taxonomy Extension Schema 
101.CAL**XBRL Taxonomy Extension Calculation 
101.DEF**XBRL Taxonomy Extension Definition 
101.LAB**XBRL Taxonomy Extension Label 
101.PRE**XBRL Taxonomy Extension Presentation 
*    This exhibit is a management contract or a compensatory plan or arrangement, which were filed as Exhibits to the Company’s Current Report on Form 8-K filed January 3, 2017.
**    XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of section 11 or 12 of the Securities and Exchange Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise is not subject to liability under these section.


45




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  QUALITY SYSTEMS, INC.
Date:January��28, 2016January 25, 2017By: /s/ John R. Frantz
   John R. Frantz
   Chief Executive Officer (Principal Executive Officer)
    
Date:January 28, 201625, 2017By: /s/ James R. Arnold
James R. Arnold
Chief Financial Officer (Principal Financial Officer)
Date:January 25, 2017By: /s/ John K. Stumpf
   John K. Stumpf
   Interim Chief FinancialPrincipal Accounting Officer (Principal Accounting Officer)






4638